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EXECUTIVE SUMMARY 
 
This qualitative study will analyse the views of two types of medical scientist working in one 
region of New Zealand. The first group, medical scientific officers (MSO) who are employed 
by hospital and university laboratories, do research on diseases to develop vaccines and 
medications. The second group, medical laboratory scientists (MLS), provides the test results 
essential for use by clinical medical staff in the detection, monitoring or prevention of disease. 
(There is some crossover of duties). The 35 scientists interviewed were told the emphasis was 
on issues which help or hinder their work and in particular matters of ‘bureaucracy or paper 
work’. The aim was to find what scientists, management and government need to do to 
provide an effective environment toward meeting the New Zealand government’s goal for 
growth in science and biotechnology as an export earner. 
Overwhelmingly, the claim was made that scientists were beset with too much unnecessary 
management and government bureaucracy. Medical scientific officers (MSOs) believe 
hospital managers are cutting back on scientific officers and replacing them with lesser 
qualified medical laboratory scientists (MLSs) to the serious long term detriment of the 
nation. They regard science as a poor option for young people to enter, much better tenure is 
needed, as is more freedom to carry out productive research without people outside of their 
specialty telling them what they can or cannot do. A key finding is the strong need for more 
clinical direction. Ideas with potential are not acted on quickly enough because ideas are tied 
up inappropriately in intellectual property secrecy. Innovative MSOs and MLSs as well as 
medical doctors need more support from management and peers to develop new ideas. 
Of great concern was the finding from nearly all MSOs and some MLSs, that there was deep 
mistrust of management. They wanted a more congenial management and thought there 
needed to be more management co-operation between universities and hospitals. E.g. have 
common administration and services. The good news is that there are some groups working 
well and these provide a successful model for others. Finally, as permission for this study was 
willingly given by laboratory and university management, this indicates a willingness from 
management to help scientists. However, as the theory will show, until the lack of trust is 
overcome, some management improvement programmes may fail. 
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1.0 Introduction 
 
1.1 Background 
This qualitative study will analyse the views of two types of medical scientist working in one 
region of New Zealand. Firstly, Medical Scientific officers (MSO) who are employed by 
hospital and university laboratories, do research on diseases to develop vaccines and 
medications. Secondly, medical laboratory scientists (MLS) who provide the test results 
essential for use by clinical medical staff in the detection, monitoring or prevention of disease 
(There is some crossover of duties). The 35 scientists interviewed were told the emphasis was 
on issues which help or hinder their work and in particular matters of ‘bureaucracy or paper 
work’. The aim was to find what scientists, management and government need to do to 
provide an effective environment toward meeting the New Zealand government’s goal for 
growth in science and biotechnology as an export earner. 
The 17 MSOs interviewed comprised about 20% of the total number employed by district 
health boards and universities in New Zealand. This excludes physicists. The 18 MLSs 
interviewed represented only about 1.5%. However, this research is qualitative and not 
dependant on statistical reliability.  
Highlighted, are some challenges and controversy over directives and challenges faced by 
government, universities, hospital and private medical laboratories to be effective in carrying 
out medical science work.  
The literature review will show there is much written about the lack of funding for medical 
scientists worldwide. As the issues are not just about a lack of money, this study aims to look 
at other issues which need to be addressed to help both managers and medical scientists at the 
personal level. It is anticipated that the research will hopefully have positive implications for 
Government, Hospital Boards, laboratory managers, co-operating businesses and scientists 
themselves.  
 
It is also a process study. By process, I take from Van de Ven’s (1992) third definition and 
from Chia and Langley (2004), who say process involves considering phenomena 
dynamically in terms of movement, activity, events, change and temporal evolution. By 
focusing on “something that people do”, Whittington, Jarzbkowski, and Johnston et al,  (as 
cited in Langley, 2007), we take a ‘strategy in practice’ perspective which adds a focus on 
micro level activities and practices. However, this dissertation aims to also apply temporally 
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evolving phenomena at a variety of levels such as the individual, organisational, sector, and 
issues related to strategy content. We are certainly looking at non linear effects under 
complexity. For example, there are political negotiations and the possible destruction of 
organisational cultures and activity systems. Variance based theories, while useful, tend to 
ignore complexity (Barney, 2001; Langley, 2007). Finally, while some process researchers 
have emphasized the importance of relating processes to outcomes, it should be remembered 
that “outcomes” are often rather artificial staging points amid never-ending processes and can 
be analysed as such (Langley, 2007). 
   
2.0 Setting the Scene 
2.1 The Problem of Lack of Money for Health Research 
Health care systems across the world are in a state of permanent revolution as they struggle to 
cope with multiple pressures arising from changing demography, new technologies, and 
limited resources (Hunter, 2008). While other nations have rushed to increase their already 
high investment in research, science and technology, New Zealand’s investment has dropped 
as a proportion of GDP and is now in the bottom third of OECD countries, spending about 
half the 2003 OECD average (OECD, 2007). 
Research funding in New Zealand is 12 times less than some OECD countries, and may soon 
affect the health of the population (Auckland-University, 2008). This report by the deans of 
two universities, says that funding provided by the New Zealand government for health 
research is currently equivalent to NZ$10.20 per capita. In comparison, funding in Australia is 
around NZ$34.60 per capita, with NZ$54.30 per capita in the UK and NZ$126 per capita in 
the USA.   
In New Zealand, medical research is primarily funded through the Health Research Council. 
This funding has remained at a static level for the past four years despite research costs rising 
by almost 9% per year. Around 85% of submitted projects do not receive funding. 
"The lack of health research funding in New Zealand needs to be addressed," says Professor 
Peter Joyce, Deputy Dean of the Faculty of Medicine at the University of Otago. "Over the 
next two years, this lack will translate to more of the health workforce moving overseas, 
attracted by higher levels of funding and the facilities these can provide. This will not only 
have a huge impact on the level of care available, but will also affect the ability of the 
academic sector to train new doctors." 
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2.2 Leadership 
From Science New Zealand (2007), we read that more money is necessary, but this is not 
sufficient. Other areas also need attention. All can be addressed in short order given 
leadership across the political, business and science spectrum. Initial discussion with medical 
scientists, revealed they had very serious concerns with the way management and government 
were ignoring the collective voice for the future of New Zealand medical science; both for the 
health of New Zealanders and the competitive economic advantage they could contribute if 
barriers were removed. Several participants said a ‘revolution’ had begun – that is; some 
scientists were now standing up to their employers and the government to forcefully make 
their point known. 
 
The MLS group (not MSOs) had recently been on strike, not only for better recognition but 
because they believed laboratory services were being compromised and New Zealanders 
would lose because of this. While some scientific officers are mainly doing research, others 
have a dual role of research and also routine laboratory testing.  
 
In March 2008, a report from the National Science panel of the Royal Society of New Zealand 
was published by a group of highly respected top scientists.(RSNZ-National-Science-Panel, 
2008). Among the 10 points they made, was one that scientists were faced with crippling 
bureaucracy. Another was that science could, and should be seen as much more important in 
contributing to the economy. 
 
2.3 About This Study 
This dissertation analyses data from interviews with 35 New Zealand medical scientists. This 
provides a window into what one sample group in the main centre of the South Island of New 
Zealand think.   Literature is used to investigate possibly overlooked practical ways of how 
the goals of the government and management can be met for medical science.  
 
2.3.1 The advantage of an external study 
Why carry out a study by an external person when each department has their own managers 
doing internal reviews? Previous studies suggest research within provides grounding of the 
research problem in a particular situation, while research from outside provides empirical 
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evidence of the pervasiveness and boundary conditions of the problem. Van de Ven, (2007) 
claims both kinds of insight are needed to ground a problem up close and from afar. Gathering 
data from across departments and organizations also allows cross analysis and comparison, 
thus enriching the research. 
 
3.0 Literature Review of Issues That Beset Medical Scientists  
 
3.1 Introduction 
Many tensions are evident in contemporary health policy including: the funding of health 
systems and the changing mix of public and private arrangements; the capture of medicine by 
management; the imbalance between health and health care; and the growing emphasis on 
markets and competition in health care systems (Hunter, 2008). 
 
This chapter looks at literature describing the changing demands over the last two decades 
made upon medical laboratories and medical research science. It discusses issues besetting the 
medical scientist. Starting with a global view, it illuminates the changing public demands 
placed on both scientists and medical laboratories. Governments and funding administrators 
demand accountability. Astute laboratory managers are demanding changes, which mean new 
skills and new business models. The demands come from both internal and external sources 
and the emphasis is to produce ‘outcome’ based science.  
 
Discussed, is commitment and trust between scientists and their organisations. Next, a review 
of some Canadian, U.S.A., and Australian studies provide informative debate, presenting a 
scene showing that all Medical Laboratories and researchers face similar constraints – and 
also opportunities. Then there is a brief look at Europe’s 6th Frame network and an evaluation 
of what some Australian scientists say. Funding contestability is a major issue, and this is 
discussed throughout the review. There is also acknowledgement that some of the public are 
against government funding for never-ending scientific research and the case for tax payer 
accountability is noted. Finally the essential ideas from several New Zealand organisations 
such as the funding bodies and the Royal Society Science report are discussed. What are the 
issues that beset medical scientists? What can be done to help them? 
 
From this exploration we discover a great deal of effort has gone into managing funding in 
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what is, for each country, a limited government research budget. The budget may be limited, 
but there are additional challenges for both New Zealand and Australia owing to distance 
from markets and small populations, 20 million in Australia and 4 million in New Zealand. 
Neither New Zealand nor Australia, have the local giant private companies of North America 
or Europe to provide on shore fund backing. The small population can also make it harder to 
get enough local participants to carry out large population sample medical research tests. 
However, even a small country like New Zealand with determined research groups can offer 
advantages to overseas partners. The New Zealand government is trying to grow these 
benefits to create competitive advantage. 
 
3.2 Changing Global Needs from Medical Laboratories 
Without doubt the pressure is on clinical laboratories. The pressure is on to reduce costs and 
enhance efficiency as lab services are increasingly becoming commoditised. This is a global 
trend forcing clinical laboratories to adapt. Bossuyt, Verweire, and Blanckaert (2007), suggest 
that to prepare for the future, laboratories need to not only form alliances and networks, but 
also consolidate and integrate or outsource. More importantly, they argue, laboratories need to 
create additional value by providing knowledge services related to in vitro diagnostics as 
information on laboratory services is globally available, and consequentially clinical 
laboratories face worldwide competition. 
 
3.3 New Skills: The Need to Become Information Literate  
According to Wilcke (2008), clinical laboratory scientists, more than any other group of 
health care specialists, depend heavily on computers for clinical decision making. It can be 
difficult to glean appropriate information from large amounts of data. Wilcke highlights that, 
and a new competency laboratory workers need is the ability to be truly ‘information literate’. 
Medical scientists must learn how to separate and translate data into information and 
information into knowledge. Glib though this sounds, Wicke points out that the future clinical 
laboratory scientist must be well able to demonstrate information literacy in order to separate 
the important and relevant from vast amounts of data and pass this on to clinicians. A USA 
study agrees. Harrison and McDowell (2008), evaluate the status of USA hospital laboratory 
Information Systems. They say these systems are critical to high quality healthcare services, 
as laboratories give most of the information needed for clinical decision making. This article, 
at time of publication in 2008, claims to provide the most current information available on the 
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US hospital laboratory information systems applications. 
 
3.4 New Business Models Needed 
Bossuyt, Verweire, and Blanckaert (2007), highlight that new business models are needed for 
the Clinical laboratory. They support an idea by Freidman (2001), and his model for clinical 
laboratories that is based on establishment of collaborative laboratory networks. Freidman 
also proposed a total laboratory solution that consists of both horizontal and vertical networks, 
although variants of this already exist. 
 
3.5 Core Competency 
The paradox with outsourcing laboratory work, is that extreme levels of outsourcing lead to a 
virtual organisation. The risk with this is it may degenerate into a ‘hollow’ organisation that 
can not adapt to changing circumstances. This scenario, which is recognised by Bossuyt et al 
(2007), is exactly what Prahalad and Hamel (1990) talk about; that if core competences are 
embodied in core products, then the more these products are outsourced, the greater is the 
likelihood of erosion of core competences. Thus, if laboratory professionals merely focus on 
analytical aspects, then their professional status will become marginalised when tests are 
outsourced. Likewise, clinical pathologists who focus mainly on analytical and technical, 
organisational, and managerial aspects, rather than clinical aspects, should prepare for the 
future by redirecting their thinking and engage more in clinical innovation. A new core 
competency of a clinical pathologist therefore, should be to improve patient care by giving 
complementary knowledge services related to diagnostic testing. (Plebani, as cited in Bossuyt 
et al, 2007) 
Also recommended by Bossuyt et al (2007), is that Laboratory professionals could 
differentiate themselves, not only by their technical skills, but also by being involved in the 
creation, distribution, and application of knowledge related to laboratory aspects of patient 
care (if this is not already done) and such extra service should be recognised and implemented 
in the business strategy. There are other recommendations that the authors make, but they 
conclude with a statement that while efficiency is a prerequisite for success, it is not a 
guarantee - the relevant standard is actually value (Prahalad & Hamel, 1990), and to add 
value, the core competency of laboratory professionals must be refocused on providing 
additional knowledge services related to invitro diagnostic services. 
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3.6 Management Theory 
 
3.6.1 Porter’s Five Forces Model  
Management teachers have long appreciated the tension all business organisations are under. 
Porter (1980), presented his ‘Five forces of competition framework’ which is still helpful for 
analysing the profitability of an industry, as determined by five sources of competitive 
pressure. I.e. there is competition from substitutes, competition from new entrants, 
competition from rivals, the bargaining power of suppliers and buyers. Today’s laboratories 
face these competitive pressures as stakeholders demand accountability. For example, fiscal 
pressures which lead to cost containment measures in Health, citizen pressure resulting in 
more assertive and demanding citizens who want rapid improvement in health care and 
international pressure from international management consultancy firms. These ideas possibly 
come from NPM (new public management) drivers. (Hunter, 2008) 
Some thoughts on this from MLSs interviewed suggested internal pressures come from 
changing demographics of the workforce and the patients. I.e. The average age of both 
scientists and the patients are older now than before. More health care will be required 
because the average age of our population is getting older and people are living longer. The 
scientists also thought there was a lack of interest in science and fewer students were 
completing science based entry courses. They suggested there are politically expedient 
solutions rather than well thought out policy as the Government is sensitive to public opinion 
around health issues in some areas more than others. Another suggestion was that there is an 
expectation on medical laboratory scientists to learn the latest techniques of testing assay 
types where they have been introduced in only partially validated states. There is pressure to 
try new technique technologies before they are fully validated. 
 
3.6.2 Strategic Analysis Structure-Swot-Two Way 
Let us consider a basic strategic analysis framework as presented by Grant (2005). We can 
apply this framework, which views strategy as forming a link between the firm (Laboratory) 
and the outside environment. The laboratory has three key characteristics: 
• Goals and values 
• Resources and capabilities 
• Organisational structure and systems 
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The outside environment for the laboratory comprises the whole range of economic, social, 
technological, political and environmental factors that influence its decisions and 
performance. The core of the Laboratory’s outside environment is its industry, which is 
determined by relationships with clients, competitors and suppliers. This is where most 
strategic decisions are made. The business strategy then, is to determine how the laboratory 
will deploy its resources within its environment to satisfy long term goals, and with how to 
organise itself to implement that strategy.  
A widely used tool is SWOT analysis (strengths, weakness, opportunities and threats) and this 
tool classifies various influences on a firm’s strategy into the four categories. Grant believes 
there are problems with making arbitrary classifications like this, as strength may also be a 
weakness. For example, the laboratory may implement stricter Intellectual Property Protection 
on some of its development. While this may be strength, it could also be a weakness (or a 
threat) as some scientists may respond by not sharing ideas and they could also develop 
mistrust of management. I agree with Grant who favours strategic analysis with a two-way 
classification of internal and external factors. It is the rigour and depth of the analysis of these 
factors that determines the effectiveness of the results. 
 
3.7 Non-Profit and Profit Enterprises and Culture of Discipline 
One of the anecdotal criticisms of management made by health workers in New Zealand over 
the last 15 years, has been that hospital management sometimes forget the health system is not 
a profit making enterprise and the changes made have not always been appropriate to the 
health of the nation. To consider opportunities for non profit organisations, Jim Collins, who 
is founder of a management laboratory in Colorado, USA, recommends some helpful ideas 
(Carpenter & Collins, 2006). Collins has many views on good to great principles between not 
for profit health care and the other social sectors. As an example, he says it makes perfect 
sense to measure greatness by cumulative returns to investors in a business, whereas in the 
social sectors, the critical question is how effectively do they deliver on their mission and how 
do they make a distinct impact, relative to their resources. Collins claims great companies first 
build a culture of discipline, and then make a business model that fits right at the intersection 
of three circles: what they can be best at in the world, a deep understanding of their economic 
or resource engine, and the core values they hold with deep passion. A key to sustained 
resources is brand reputation, so key supporters will believe not only in the mission, but in the 
capacity to deliver on that mission. This is relevant to our study, as the laboratory carries out 
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both non profit as well as profitable services. Brand reputation of the laboratory is therefore a 
competitive advantage and management should pay attention. For example, a medical 
laboratory scientist or technician with a business idea may well be able to help improve 
efficiency and build the brand reputation of the laboratory. Even an unsuccessful attempt may 
stimulate motivation and enthusiasm. See the Hawthorne effect (Makamson, 2000). 
 
3.8 Commitment to Work 
On improving laboratory efficiency, a USA article called ‘Factors that impact on clinical 
laboratory scientists’ commitment to their work organisations’, Bamberg, Akroyd, and Moore 
(2008), provides useful information. It is useful because the authors set out to assess the 
predictive ability of various aspects of the work environment for organisational commitment. 
Only respondents obtaining CLS (clinical laboratory science) certification by NCA (National 
Credentialing Agency for laboratory personal in the USA) from January 1997- December 
2006 and who worked full time in a clinical laboratory were included in this study. The 
results of 427 respondents which was a 22% response rate indicated a less than optimal level 
of organisation commitment to employers, which were predominately hospitals by CLS 
practitioners. The mean age of participants was 34.8 years. Results suggest there will be 
continuing retention problems for hospital laboratories.  
 
One value of Bamberg et al’s (2008) study in the USA, is their discovery of a lack of research 
on the organisational commitment of Clinical laboratory scientists and a lack of knowledge of 
factors that may predict or limit employee’s commitment to their workplace - information that 
could be used by managers to better direct strategies to improve retention of their employees. 
In New Zealand’s case, it should be very useful to find out just what does motivate scientists. 
Motivated people are more likely to help carry out the efficiency improvements our literature 
review suggests is needed. For the Bamberg et al (2008) study, results showed that laboratory 
employees had more organisational commitment for a USA clinical laboratory work 
environment when they had strong organisational support and supervisors who demonstrated 
transformation leadership behaviours. 
  
3.9 More Trust in Scientists Needed 
New Public Management (NPM) theory has been popular with governments around the world 
(Aucoin, as cited in Davenport & Bibby, 2007). According to the authors, the public choice 
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theory platform of New Zealand’s NPM model is inherently based on distrust and this distrust 
impacts on the environment its application is intended to manage. This distrust of permanent 
bureaucracy and of those not held directly accountable for their outputs results in a 
breakdown of social capital and collaboration, say Davenport and Bibby (2007). They 
conclude that with the recent devolving of funding for New Zealand Crown Health Institutes 
(CRIs), while still contested, indicates that after 14 years more trust needs to be built into the 
research system, as the lack of trust in scientists’ ability to make strategic decisions about 
what research should be carried out has been a major element of disquiet about New Zealand 
reforms. A Science Manifesto or Plan for the Recovery of New Zealand Science (RSNZ-
National-Science-Panel, 2008) emphatically recommends that to overcome some of this 
distrust, cooperation rather than competition should be promoted. This also means assisting 
scientists’ development, particularly early in their careers. There has been distrust of 
government and management partly because there has not been a commitment to address 
these challenges. Some further discussion on why distrust exists is in the concluding theory 
section of this dissertation. 
 
3.10 The Significance of Mutual Trust 
In his concluding chapter for a doctoral thesis looking at change in 4 different plants of the 
New Zealand meat industry, Addison (1998) writes that when an organization or some part of 
an organization is undergoing change, the environment, by definition becomes more dynamic 
and turbulent, and according to contingency theory, an organic operating mode is called for. 
Spender and Kessler, (as cited in Addison, 1998), apply this to the area of innovation 
management, and if we accept that innovation is a type of change, then according to Addison, 
it is legitimate to extend its application to change management in general. He uses the term 
‘prior context’ which comprises the building block of change, and this has a significant effect 
on the success of any change management operation. Addison proposes that there is a positive 
and a negative prior context. The positive is characterized by mutual trust, informal 
communication and problem solving, empowerment and perceptions of ownership. The 
negative on the other hand is characterized by low mutual trust, formal communications and 
problem solving. The most energizing and driving of these factors is the mutual trust. There is 
a difference here in that scientists are better qualified academically than meat industry 
workers and they may possibly challenge management more easily. However, Addison says it 
is human qualities possessed by management (rather than technical issues) that underpin the 
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quality and nature of prior context. I suggest this is supported by Maslow’s hierarchy of needs 
(Huitt, 2004) where humans need to feel a sense of belonging and acceptance (social needs), 
before the next levels of needing esteem, then the need for self-actualization, which  is the 
final need that manifests when lower level needs have been satisfied. I believe self 
actualization is where the jump to innovation and attaining a new level of output from both 
management and medical scientists is most likely to occur. Addison’s thesis lends support to 
reasoning that mutual trust (which according to Maslow is a building block upon which self 
actualization rests) is therefore very significant indeed to successful change in the innovating 
laboratory. 
 
3.11 Why it is useful to look at a global perspective: Convergence thesis 
In the simplest form, the convergence thesis postulates that as economies develop along 
modern lines, certain common characteristics and patterns emerge. Developed countries 
would become more and more alike in economic and social structures (Marshal, 1998; 
Preston, 1993). While Preston was postulating that the convergence thesis strongly suggested 
social security systems in developed countries would become increasingly similar, it could 
also be used to support the theory that the management of medical science laboratories would 
become increasingly similar. Perhaps the convergence thesis is now past its usefulness? This 
is because we can take the converse view and look at how laboratories or some modern global 
organisations actually are and see that convergence has happened but they now need to 
divergence enough to develope competitive advantage in the global arena.    
An interesting book called ‘The Health Debate’ (Hunter, 2008) supports the convergence 
thesis with the example and acknowledgement of the global reach of ‘New Public 
Management’ (NPM) and its association with public sector reform in areas such as Health. 
James and Manning, (as cited in Hunter, 2008), see NPM is an example of the globalisation 
process in public management which has roots in a set of pressures common across countries. 
These acute pressures are: fiscal, citizen, government and from ‘international management 
consultancy firms and public management organisations’. Hunter explains how the 
consultancy firms present their ideas to public managers as ‘best practise’. McKinsey for 
example, have offices in over 100 countries and they can rapidly and consistently present 
‘market-based’ ideology in which private sector practice is claimed to be superior. Doing this 
also provides a model for the transformation of allegedly underperforming, low quality public 
services and weak public sector management. It is easy to see how these international 
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management consultants cross national boundaries and cultures and one can see that the 
nation state is partly being replaced by the ‘market state’. According to Bobbitt, (as cited in 
Hunter 2008), the nation state will disappear. Bobbitt claims the nation state is seen as too 
rigid and conforming. However, different cultures will adapt the market state in different 
ways, and for New Zealand, with its small population size and desperate awareness of the 
need for new and growing export markets; this makes it even more imperative to be utterly 
determined to succeed. 
 
3.11 Canadian Study-Innovation and Critical Inquiry 
Because of the importance of convergence and consequently the rapid new opportunities in 
the global market, it is useful to study how other countries have progressed in Medical 
laboratory areas. 
‘No one can say with confidence just where scientific culture is going’, wrote David  
Holdsworth (2002) in his important essay on ‘Science, Politics and Scientific Policy in 
Canada’. Holdsworth’s core thesis arises from the tension between the autonomy of science 
and the authority of politics. He concludes that the meaning of scientific practice and its 
relevance for public policy should be shaped by ‘ongoing critical discussion’ within civil 
society- a discussion that should not be dominated by either the State, or markets. The three 
themes highlighted are: 
• The concept of science policy 
• Our understanding of the relationship of science to public policy 
• The emerging notion of innovation as a rhetorical centerpiece of current public debates 
about science. 
In writing about science policy, Holdsworth gives background to the rise and fall of Canadian 
science policy, and cautions that the term ‘science policy’ must remain informal. In the 
1970’s science was to become ‘strategic’, and this exacerbated the tension between political 
authority and scientific discovery. In the mid 1970’s the National Research Council broke up 
after 60 years and 3 independent institutions were formed. One, the Natural Sciences and 
Engineering Research Council of Canada (NSERCC), took over the funding role for Canadian 
Universities. The second was the Science council, and the third was what remained of the 
National Research Council (NRC). 
 
Now for Holdsworth’s main point of relevance - Innovation is the dominant rhetorical 
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element in much of the current Canadian science. But as expounded in this essay on Canadian 
science, innovation according to Holdsworth can mean just about anything one wants it to 
mean and the core meaning is lost. The general point is that a generic and uncritical notion of 
innovation is philosophically and politically problematic. If it is linked closely to markets in a 
way that minimises the capacity of civil society and the state to assess the outcomes of these 
processes and if it eliminates open discourse but suppresses established frameworks of 
evaluation, then we abandon the very possibility of critically understanding the 
transformations of society which innovation can bring about. Holdsworth says there is a sense 
of suspicion in Canada about the political agenda and the notion of critical inquiry has lost 
value. At the same time, from the perspective of traditional politics, scientists’ resistance 
seems equally uncompromising. 
 
3.12 Who Owns Canadian Science? - The Public/ Private Divide & N.C.E. 
At the time Holdsworth published his essay, Atkinson-Grosjean, (2002), had published her 
work on “Canadian Science at the public/private divide: The NCE experiment” (NCE stands 
for National Centre of Excellence).  
Her essay traces the relationship between politics and science in terms of public/private and 
basic/applied distinctions. She asks, ‘When the state becomes a partner with academe and 
industry in privatising research, does it make sense to keep distinctions between public and 
private, basic and applied? Are they differences that make no difference? So what if the 
distinctions are abandoned?  
This is a very relevant and important question that I believe we need to strongly debate in 
New Zealand which has a far smaller economy with much fewer resources than Canada. 
The author asserts that the policy of privatising public science and its institutions in Canada 
has proceeded ideologically rather than by rational calculation. Historically, the trust in the 
public institution of science rests on trust in the private morality of sciences individual 
practitioners. The author asserts that the nature of scientific knowledge rests on the collective 
construction of a collective good, which means a reliance on the work of others, and therefore 
within this ‘moral economy of truth’, public and private, scientific and social, become 
inseparable. New Zealand needs to listen to Holdsworth and Atkinson-Grosjean as they 
perhaps unwittingly give a prophetic word here for New Zealand.  
There are more arguments which Atkinson-Grosjean raises when explaining the emergence of 
the NCE programme formed in 1990, and these may be relevant in the discussion of data 
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results. It is worth mentioning the Canadian Genetic Diseases Network (CGDN). The effect of 
NCE philosophy on practice here shows many believe the leadership of the scientific director 
as outstanding, and this was the single most important determinant of CGDN’s success. We 
should take note of this. There are extensive network linkages including 11 universities, 6 
federal and provincial agencies, 11 hospitals, 8 industry partners, 32 industry affiliates, 34 
non profits and other affiliates and several spin off companies formed by the network.  
There are critics of the programme though. Again there are constant tensions at all levels due 
to the values of science and the values of commerce. One scientist remarked that to ensure 
survival you have to be an entrepreneur. This is probably a productive tension though. In 
concluding, Atkinson-Grosjean says there is little point in engaging in the ‘sociology of 
accusation’ about the moral decline of public scientists seduced by the profit motive. Things 
are not that simple. This Canadian case article is relevant for New Zealand, and I believe it is 
arguable that the ‘tall poppy’ syndrome that the ‘sociology of accusation’ arouses is possibly 
stronger in New Zealand than in Canada. 
 
3.13 Europe’s 6th Framework Programme (FP6) 
According to some scientists, (Nature-Neuroscience, 2004) funding may be a big factor 
affecting medical scientists’ motivation and hence work output. We now briefly look at an 
editorial, ‘Time to reform European science funding’ (Nature-Neuroscience, 2004). Even the 
Europeans lament that their young scientists are moving to America and over one third are 
staying there because it is easier to secure post- doctoral jobs, and not only do they more 
easily get jobs, but the pay is much higher. The author claims part of the problem is with how 
funds are administered in Europe. One claim he makes, is that only about 10% of 
neuroscience funding in Europe is from the EU. Funding basic research is not a priority, and 
the official goal of the 6th Framework Programme (FP6) is to ‘strengthen the scientific and 
technological basis of industry and to encourage its international competitiveness’. The FP6 
programme emphasises applied science. Projects, including ones on synaptic information 
processing, neuroimmune disorders, dyslexia and sleep, are defined in an extensive process of 
consultation involving national programme committees and scientific advisory boards. The 
main goal of FP6 is to foster cross border co-operation, so applications must be submitted by 
a consortia of scientists from three different countries. If the consortia are successful the grant 
money is given with a legally binding contract which spells out the tasks and expected results.  
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So what is the opinion of people involved in the FP6 programme? One reviewer found the 
process frustrating because there was not enough money and excellent projects missed out. 
Also a large portion of funds are spent on administration because of the large scale 
collaboration from three different countries. On the other hand, one neuroscientist at the 
French Commissariat for Atomic Energy believes the framework is useful in complicated 
areas with far reaching implications, such as prion diseases where research must be structured. 
The benefit with some cases like this, is not directly to fund research, but to coordinate 
consortium members, jump start risky projects and help groups apply for 3rd party funding. 
However, many Europeans find the FP6 too inflexible and at odds with scientific excellence. 
Nevertheless, nearly everyone, according to Nature Neuroscience (2004), supports 
neuroscience funding on a European level, and the programme is currently being reviewed to 
improve funding, and reverse the brain drain and even attract overseas scientists to Europe. 
 
3.14 Lessons from the EU for Australia and NZ 
Although published in Nature Immunology two years earlier than the editorial just described, 
‘Basic Science funding in Australia: Lessons from the EU’ (Stumbles, Upham, & Nelson, 
2002), explains that many of the key features and problems of the FP6 European Union are 
mirrored in Australia. The main concern to the Australian authors of the FP6 approach was 
the peer review problems, and the stifling of innovation exemplified by Australia’s small 
population and lack of non government funding sources. The authors believe the potential 
exists for these systems to act toward preserving the status quo. 
 
3.15 Australian CSIRO and People Who Innovate - Australian Difficulties 
While our study is on medical science, it is worth looking at an Australian study that raises 
interesting points but which also includes traditional Australian science fields in agriculture, 
earth science, life science, as well as medical sciences. Called ‘Innovation  agents and 
innovation tracks: CSIRO research scientists and their peers’(Marceau & Turpin, 2007). This 
study from 2003-2004, is of 515 research scientists. Respondents worked mainly in the public 
sector with a significant number in Commonwealth agencies, notably the CSIRO, 
(Commonwealth Scientific and Industrial Research Organisation), is Australia's national 
science agency, which is the biggest single employer of scientific researchers in Australia. 
 The authors remind us that it is ultimately people who innovate, and these innovators are 
often scientists and technologists. The impact of monies for research on technological 
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innovation levels in any country depends greatly on the willingness and the capacity of 
researchers to take risks with their career paths. This is significant. Marceau and Turpin 
(2007) say that current science policies show little concern for the choices facing scientifically 
trained people in Australia. Many younger scientists face difficulty deciding whether to 
remain in science when they have held several post-doctoral positions, as they see the future 
as insecure. The authors’ argue that Australia provides too few secure, well paid opportunities 
for researchers if it is to stay capable in key areas, although some such as biological science 
have done well, possibly because of its expectation for commercial outcomes. That is, 
because funding bodies can see good potential financial returns from certain biological areas, 
they are prepared to fund and provide secure tenure to researchers working in those areas. 
This follows the move in recent decades to fund more strategic and applied research, and less 
basic pure science.  
Uncertainty about career paths is evident, and respondents to the survey were on relatively 
short contracts. Long term funding was the major issue confronting scientists in Australia 
according to 84% of participants, but the orientation of scientific practice was also important. 
Data suggests that researchers in science and technology are not particularly interested in 
working with external clients, and perhaps this is because of the complex administrative 
procedures with collaborative opportunities. They are also much concerned about the 
conditions of doing science in Australia. Significantly, more than one third of respondents 
resented the focus on applied over basic or pure research. 
 
3.16 Funding Contestability – Excellence Vs-Contestability 
Continuing now with Marceau and Turpin’s (2007) Australian study, here are points they 
make about funding contestability vs. community return: 
 Increasing the contestability of funding is often thought to encourage ‘excellence’ in 
scientific endeavor because of continuous peer review. This, according to Marceau and 
Turpin, runs in parallel with policy makers’ increasing focus on the ‘community return’ from 
commercialisation of research results, which have less emphasis on peer review but more on 
reward for the profitable use of commercial results. This is very interesting in that these two 
policy directions may eventually prove to be incompatible. For science in general, the authors 
then relate research by Tijssen (2001), that claims the linear relationship between scientists 
and innovation dominates policy makers’ minds, despite claims of  long available evidence 
that the interplay between scientific research and technological development is a non-linear 
  
17 
 
 
 
process mediated by a complex system of social, cognitive and organisational factors.  
Relevant points raised were that the most published scientists eventually move away from 
research activities as they progress in their careers. Greater contestability for funding will 
decrease the time on direct research and accelerate the loss of time for mentoring young 
students and scientists. More contestability also means career uncertainty and this will 
discourage bright people from entering science research.  
 
3.17 Australia and New Zealand: Changes to Science Policy In The 1990’s. 
Administrative changes and criteria of funding available to scientists  
Bringing the contestability issue  back to New Zealand, Davenport and Bibby (2007) write 
about the life and times of the Australian CSIRO. In this paper there is significant history of 
the New Zealand Crown Research Institutes (CRI’s). These were formed in 1992, a time 
when major change was made throughout the public sector. Interestingly Australia did not 
follow the path into forming CRI’s.  For an informative paper on the New Zealand Science 
and innovation system, I refer the reader to ‘The politics of discourse: Marketing of the New 
Zealand science and innovation system (Leitch & Davenport, 2005). This paper examines the 
politics of change played out by discourse dedicated to transforming the science and 
innovation arena. One unintended value of this paper that I see is to reassure the busy New 
Zealand scientist that, possibly unknown to them, researchers behind the scenes are looking 
at, analysing and comparing world data to try and best improve the lot of the nation. This also 
highlights the importance of the individual and group value of ‘speaking out’ and making 
recommendations to politicians. 
New Zealand in the 1990’s had several major doctrines stemming from the globally popular 
‘New Public Management’ (NPM) or public choice theory (Wikipedia, 2008). These 
included: 
 
• Hands on professional management in the public sector 
• Explicit standards and measures of performance 
• Greater emphasis on output controls to stress results rather than procedures 
• Disaggregation of the public sector units to create efficient and manageable units and 
separate provision interests 
• Greater public sector competition 
• Stress on private sectors styles of management practice and use on ‘proven’ private 
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MoRST (the Ministry of Research, Science and 
Technology) formed. 
  To give Policy advice to: 
FoRST (Foundation of Research, 
Science and Technology) formed. 
Funding (purchasing of outputs) to: 
Performance of research 
CRI’s (Crown research Institutes) 
Universities 
Research associations & organisations 
     Figure 1 
sector management tools 
• Stress on greater discipline and parsimony in resource use –do more with less. 
 
3.18 New Zealand Break-Up of DSIR and Establishment of MoRST (Fig 1) 
What this meant for science, was more accountability in science investment necessitating the 
break-up of the Department of Scientific Investment and Research (DSIR). This is when 
MoRST (the Ministry of Research, Science and Technology for New Zealand was formed. 
The organisation chart of today is shown in Figure 1: 
 
 
The Crown research Institutes (CRI’s) were to have a broad focus and be flexible and 
vertically integrated over the value chain. The CRI we are interested in here for medical 
science is ESR (Institute of Environmental Science & Research Ltd) and Industrial Research 
Ltd (IRL). There are many research groups providing funding and support. The CRI’s are 
explained in the next chapter but their instruction from government was to perform research 
of benefit to New Zealand and to be financially viable. FoRST evolved as follows: Initially its 
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focus was on excellence and the ‘elimination of useless research. In the mid 1990’s this was 
reversed to prioritise research of ‘relevance to users’. Users, rather than scientists assessed the 
proposals. Then there was a move to a funding ethos driven by ‘investment discourse’. Next it 
moved to a system of outcome based negotiated funding. It is worth noting that one former 
FRST manger stated that FRST constantly struggled with the tension between running a 
competitive funding system, a contestable allocation system, an investment function, and a 
stewardship role of maintaining infrastructure, the stability of the science provider system and 
the staff within it (Winsley, as cited in Davenport & Bibby, 2007). The previous discourse 
gives an outline of the administrative changes and criteria of funding available to scientists.  
 
3.19 Crown Research Institutes in New Zealand–A Paradox of Success 
An interesting fact to note is, since their formation in 1992, CRI’s increased revenue and 
diversified revenue sources; particularly offshore with some CRI’s creating subsidiaries 
overseas. This diversification was so successful that some CRI’s have a higher percentage of 
non –government funding than the Australian CSIRO. It is ironic that this success has caused 
some ‘independence’ from New Zealand government funding and government policy through 
MoRST (CCMAU, cited in Davenport & Bibby, 2007). However, any increases in funds from 
government sources may be short term. Accordingly, CRI’s may have become competitors 
with companies because of their increased commercial activity and commercialising their 
intellectual property instead of transferring it into domestic industry. Even though the CRI act 
states that they need to promote and facilitate the application of research results, the CRI’s 
increased commercialisation off shore has received adverse criticism with local industry. This 
has been strongly commented about to me as a researcher by at least one senior medical 
scientist.  I now state these criticisms as they are important to this dissertation.  
 
These comments from the CCMAU (Crown Company Monitoring Advisory Unit) in 2005 
are: 
• The CRI’s are storehouses of a large pool of valuable, unused IP waiting to be 
commercialised by the private sector. 
• CRI’s charges too much for access to IP when private firms are not prepared to pay fair 
market value (or in my opinion simply do not have the funds). 
• CRI’s prefer to deal with overseas firms than those that are New Zealand based. 
• End users have already paid for publicly funded IP through their taxes and should get 
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CRI intellectual property for nothing. 
 
Following this criticism, a government framework to provide more explicit direction to CRI’s 
came about to ensure amongst other things that they played a critical and increasing part in 
the development of the New Zealand innovation system and to transfer the knowledge, 
technology and capability to the local private sector. Since the reforms, New Zealand now has 
one of the highest levels of contestability in science funding in the OECD (Anderson, cited in 
Davenport & Bibby, 2007). 
Several years later, the association of crown researchers (ACRI) expressed an opinion that a 
problem with CRI’s, was the one sided nature of the science market, which meant the 
universities had assess to FoRST’s contestability funds but that the CRI’s did not have the 
matching access to tertiary sector funds, a mismatch that forced CRI’s to cut staff 
(Hargreaves, cited in Davenport & Bibby, 2007). The contestability debate began to increase 
and in 2004 an open letter to the minister signed by 725 respondents (of which 55% were CRI 
staff), showed the concern that contestability was damaging careers of CRI scientists as their 
salaries were fully contestable, resulting in poor job security.  
The prevalent concern of a dysfunctional science system prompted MoRST to launch it’s 
‘Picking up the pace’ (PUP) programme to continue constructive ongoing dialogue. From 
this, one of the papers presented was called, ‘A stable Funding Environment,’ addressing the 
fact that short term contests were getting in the way of improved collaboration. As providers 
had evolved, the contestability system had lost some of its value and the government wanted 
to place more trust in providers allowing them to make their own detailed research decisions. 
A very important point I want to make here, is the authors statement that contestability was 
now being framed as the opposite of stability and that too much contestability was not a good 
thing. This is in contrast to the belief mentioned earlier that increasing the contestability of 
funding is often thought to encourage ‘excellence’ in scientific endeavour because of 
continuous peer review. 
 
3.20 Funding Contestability vs. Stability for New Zealand Scientists 
The 2004 contestability debate got the science community responding. One question MoRST 
presented, inferred that stability was not only counter to contestability but it was also opposite 
to new ideas. Many of the responses showed the tension between what stability was or what it 
was not. The Royal society, the Public Service Association and others propounded different 
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ideas into the forum. This tension over the interpretation of ‘stability’ climaxed when FoRST 
gave details of how the PUP initiative was intended to be carried out in May 2006. The 
universities claimed the interpretation of a more stable funding would be a retrograde step and 
funding of quality science would not be guaranteed. After more publicity, universities and 
CRI researchers were set against each other in a debate as to whether universities were being 
shut out of funding, and whether the stable funding would result in the ‘ossification’ in the 
CRIs. Although the publicity and open discussion was probably necessary, it set scientists 
against scientist and in a small nation like New Zealand this is definitely unwanted as all 
scientists here should be collaborators. Lancashire, (cited in Davenport & Bibby, 2007), says 
the contest between universities and CRIs has not been good for science in general here. This 
is relevant to Medical research scientists in New Zealand as more funding is from the 
universities rather than CRI’s.  It also raises the question of how possible is it for government 
or agents acting on their behalf to be an informed purchaser of science outputs. Opinion was 
that CRI’s had been successful in their aim of becoming viable entities with major benefits to 
the nation because of the commercial focus, and these were achieved in a constantly changing 
policy environment making it difficult to evaluate the overall success of the science reforms 
or CRIs. The critical point is possibly the tension between public good and commercial focus. 
Davenport and Bibby (2007) conclude, that not only is the funding contestability issue 
hindering CRIs performance, so is the ‘lumpiness’ of funding and uncertainty of regular 
renegotiation. However, the climate of New Zealand’s science system may be shifting to 
policy to increase stability and foster capability. 
 
3.21 Myths of Public Science and Hidden Dynamics – USA Critics 
As a contrast and balance to the funding debate, there are some prominent writers in the USA 
who oppose tax payer funding to scientific research. Both writers introduced here refer to 
science in general. Rhetoric and emotion for public funded science is running high, writes 
Davidson (2006), particularly when innovation is increasingly being seen as a main engine for 
the economy. Davidson seems puzzled that few people undertake hard-headed analysis of its 
justifications. He points out that others have written about myths of infinite benefit, myths of 
unfettered research, accountability and authoritativeness and the myth of an endless frontier. 
The endless frontier is the argument that knowledge is valuable in itself and should be 
pursued whatever its moral or political consequences might be. These myths stifle the debate 
that surrounds scrutiny of the money that government spends on public science. A compelling 
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point Davidson makes, is that in hindsight it is easy to identify some pure research that has 
had great impact. However, what can not be ascertained is how much pure research has 
actually had an impact. The Australian bureau of statistics ‘Innovation in Australian Business’ 
report shows that employing a new graduate is the single largest technique innovating firms 
use to try to acquire knowledge from a university. The author argues that it is not surprising 
science provides few clear policy options for politicians. He concludes that the taxpaying 
public is entitled to more than just myths and rhetoric.  
 
Another writer hot on voicing concern at wasted money on public science is Daniel 
Greenburg. This American author has expounded his views in ‘Science, Money, and Politics: 
Political Triumph and Ethical Erosion (Greenberg, 2001). Three of his ten points are: 
• Self serving money seeking scientists routinely tell the US press the Federal 
Government is cutting financial support for scientific research and America is losing 
scientific leadership. Greenburg claims the USA is world leader in virtually every field 
of research. (Chap.5&6) 
• Lobbying for science to improve health, prosperity security and a clean environment is a 
major part of creating fear to get money to keep universities and jobs going. (Chap13) 
• When projects fail the cause may be misuse of public money, but the claim is also made 
from the backers that the defeat in getting more money granted was ignorance and 
hostility to science. 
One reviewer claims points are  better documented than most National Academy of Science 
reports (Keay Davidson, Scientific American-on the cover of Greenburg’s book), and that the 
work depicts America’s big science as a ‘classic self perpetuating bureaucracy’. 
 
The problem I see here for New Zealand laboratories is that although technology is rapidly 
changing, there are still core competences which need to be kept. For example, take the 
Boeing Airline facing designing and building the new sonic cruiser aircraft. Finite resources 
meant Boeing had to allow for the following factors: industry experience, and according to 
Walt Gillette, Boeing’s Development Programme Manager at the time, this meant the 
company needed to create a new aeroplane every 12-15 years. If this was not done, the needed 
skills and experience would be gone. Gone would be many experienced people including 
those who retired or left since the last plane was developed. Their skills and experience would 
not have been passed to the next generation of Boeing employees (Schilling, 2005) p118. This 
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was in spite of radical new technologies. On the other hand, one could argue that for 
management, new blood is necessary to change a poor organisation culture. However, could 
the thought that ‘change in leadership’ or the ‘old guard must go’ to change the culture, be 
wrongly extended over to apply to research scientists or technical workers whose experience 
is still needed? 
 
3.22 Organisation for Economic Co-Operation and Development (OECD) –as applied to 
New Zealand 
New Zealand should strengthen its support for research and innovation to boost economic 
growth, according to an OECD (2007) report.  GDP per head still lags behind the OECD 
average and growth has been mainly driven by increased labour utilisation. New Zealand has 
also not yet fully seized the opportunities of globalisation. Investment in business research 
and development (R&D) is low, less than a third of the OECD average. 
 
Looking ahead, the OECD advises New Zealand to focus on four key areas: 
• Promote innovation in the business sector. 
• Improve the business environment for innovation. The government should continue to 
improve the supply of seed and venture capital in New Zealand. The Venture Capital 
Investment Fund (VIF) and Seed Co-investment Fund are commendable initiatives 
whose operations warrant some further fine tuning. 
• Improve the effectiveness of competitive research funding. The division of labour of 
funding agencies needs to be clarified and their performance further improved. 
• Improve the governance of the innovation system. Creating an Advisory Council on 
Innovation Policy could help produce a clear, concrete national policy towards 
innovation. The way public research organisations, including Crown Research Institutes 
(CRIs) and universities, get funding could also be improved. CRIs, for example, should 
get more core funding of, say, one-third or one-half of their budget based on five-to-
seven year timeframes. At the same time, the evaluation of the CRI's funding should be 
strengthened. 
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3.23 New Zealand Organisations Which Contribute Funding or Policy for Medical 
Science 
 
3.23.1 The Health Research Council (HRC).  
 
This is the Government’s principal funding and investment agency for health research. (HRC, 
2008) As a Crown entity the HRC is responsible to both the Minister of Health and the 
Minister of Research, Science and Technology. The HRC’s primary mission is to improve the 
health of all New Zealanders through promoting and investing in high quality health research. 
Despite the absence of any increase in funding, the Statement of Intent for 2008 sets out the 
HRC’s commitment to continue building on existing strategies and policies which include to: 
• Engage the health and science sectors to assist the HRC in achieving their mission. 
• Continue emphasis on funding excellent and relevant health research. 
• Increase focus on investment in research delivering outcomes. 
• Encourage researchers to engage end-users in the research process as demonstrated 
through the Partnership Programme and District Health Board Research Fund. 
• Pursue opportunities for national and international partnership and collaboration. 
• Engage New Zealanders in dialogue about health research. 
 
The HRC distributes the majority of its funding through the annual contestable funding round. 
Research submitted through this round is untargeted: investigators are free to submit 
proposals on any topic they wish. However, all proposals received are reviewed for scientific 
merit and for relevance against the national health research priorities identified by the HRC, 
the Ministry of Health and the Ministry of Research, Science and Technology (through key 
strategic documents, such as the New Zealand Health Strategy). The Council monitors the 
investment in priority areas annually, and addresses critical gaps through a variety of targeted 
measures for research and capacity building. The quality of the research funded is assured 
through the use of peer review systems that align with international best practice for the 
purchasing of health research. 
 
In 2008, the HRC will continue the development of its strategic partnership with the 21 
  
25 
 
 
 
District Health Boards to manage the District Health Board Research Fund (DHBRF). With a 
view to sustaining this important initiative, the HRC will also invest, where possible and 
appropriate, partnership Programme funds with DHBRF funds into the translation of research 
into health sector policy and services. The Board is committed to working with the health 
research community, continuing to optimise the return on the investment in health research 
for the health and well being of New Zealanders. (HRC, 2008)  
 
The key questions from above are: 
• How do the Health Research Council (HRC) know what is relevant research? 
•  The HRC’s primary mission is to improve the health of all New Zealanders through 
promoting and investing in high quality health research. Is their vision statement too 
narrow by not adding a secondary focus on improving the medical science and 
biotechnology industry in New Zealand?  
•  Increase focus on investment in research delivering outcomes. But how do the HRC 
know what outcomes to expect and what do medical scientists have to say about this?  
 
3.23.2 Science New Zealand: Innovate or Stagnate: OECD 
Science New Zealand is an associate Crown Research Institute organisation that is run by a 
board consisting of the chief executive of all nine CRIs. Science New Zealand's purpose is to 
grow the business of respective CRIs through effective collaboration on key issues. 
The following are some points quoted from an OECD Report for New Zealand: Innovate or 
stagnate (OECD, 2007) 
 
“The primary message of this OECD Report on New Zealand’s national innovation system is 
very clear”, says the chief executive of the nine Crown Research Institutes (CRIs), New 
Zealand’s largest research organisations, “The Report is remarkably frank: New Zealand has 
no hope of regaining a place in the top half of the OECD nations if we continue to under-
invest in Research, Science and Technology (RS&T),” summarises Anthony Scott, Executive 
Director of the Association of Crown Research Institutes. He continued explaining that while 
other nations have been rushing to increase their already high investment in RS&T, New 
Zealand’s investment has dropped as a proportion of GDP and we are now in the bottom third 
of OECD countries, spending about half the 2003 OECD average. “More money is necessary, 
but not sufficient. Other areas also need attention. All can be addressed in short order given 
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leadership across the political, business and science spectrum.”  He then remarked that while 
university salaries had been boosted by central government, this was not so for staff in the 
only research organisations clearly owned by Government.  
He continued by saying that recruitment and retention issues are identified by both the OECD 
and Crown Research Institutes (CRIs) as critical issues for New Zealand’s future. He further 
states that CRI’s are very supportive of the role played by Universities as research-led 
teaching organisations with particular research strengths. These complement the long-term, 
highly sector-engaged relationships and strategic approach of CRIs. 
 
The OECD recognises that this complete reliance upon the whims of the market limits the 
capability of CRIs and under-values the global knowledge, insights and connectedness of 
CRIs. “Relying upon cyclical commodity booms is akin to relying upon Lotto for one’s 
pension.” Boldly, the OECD report claims Crown Research Institutes are better placed than 
anyone else to know the best area to focus resource for long term benefit to New Zealand. At 
the same time, the chief executives insist that all funding must be linked to performance. Mr. 
Scott then explains his reasoning that this is a key for being accountable to the New Zealand 
public who own the CRIs.  The OECD strongly recommend ex post evaluation. 
The key points from above:  
• Innovate or stagnate 
• Other areas than money also need attention. All can be addressed in short order given 
leadership across the political, business and science spectrum.  
• Recruitment and retention issues  
• All funding must be linked to performance  
• CRIs are better placed than anyone else to know the best areas to focus resources for 
long term benefit.  
• Accountability 
 
3.23.3 Ministry Of Research, Science and Technology (MORST) 
MoRST  provides policy advice to the Minister and manages the government's investment in 
research, science and technology (RS&T).Their advice covers the opportunities and issues 
that affect how New Zealand manages the delivery of RS&T.  They also provide advice on 
such areas as the structure of New Zealand's research system and investment mechanisms. 
(MoRST, 2006) The Ministry's ‘Future Watch’ work programme aims to build government’s 
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alertness to new scientific knowledge and technologies. They advise government on how to 
get value from the money it invests in research, science and technology. The government 
finances about half of New Zealand's investment in RS&T, and owns significant science 
infrastructure - notably the Crown Research Institutes (CRIs) of which the relevant one for 
medical science and technology is Industrial Research Ltd (IRL). IRL undertakes world-class 
science, development and technology commercialisation in areas of communication, 
information and electronic technologies, advanced materials and performance, intelligent 
devices and systems, biochemical technologies, energy technologies, complex measurement 
and analysis.  In some cases government departments also carry out science and research 
activity. MoRST advises the Government on opportunities for how investment in RS&T can 
deliver on the Government's priorities and it directs that investment. 
MoRST actively builds networks between research providers and the business sector.   
 
As the majority of the world's Research and development takes place outside of New Zealand, 
international research, science and technology (RS&T) links are crucial. MoRST facilitates 
international contacts between researchers and research institutions to develop collaborative 
programmes, and raises awareness of N.Z. science and technology capabilities. MoRST 
recently strengthened the science and technology agreement between the New Zealand and 
German Governments. A fund to support the exchange of N.Z. and European Union scientists 
was set up. MoRST advises government on how to get value from the money it invests in 
research, science and technology (MoRST, 2008). 
 
A key point to ask is: How do they know true value in someone else’s area of expertise? 
 
3.23.4 Statistics New Zealand: Biotechnology in New Zealand 
Published in 2005, this presents a statistical picture of the state of biotechnology in New 
Zealand (Statistics-New-Zealand, 2005). It says that often the CRI is better placed than 
anyone else to know the best area to focus resources for long term benefit to New Zealand.  
 
The biotechnology sector can be associated with innovative activities, and innovation has 
been cited as a key factor in sustaining economic growth, and in developing a more flexible 
New Zealand economy capable of competing successfully on the international stage. This 
sector is seen as important, due to its high growth potential, and its ability to contribute 
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technologies and services across the economy. Also see NZbio website for similar 
information (NZbio, 2003). 
The key point from above:  
New Zealand needs to be successful competing internationally. 
 
3.24 A Science Manifesto or Plan for the Recovery of New Zealand Science (2007) 
This was written by the National Science Panel of The Royal Society of New Zealand (NSP-
RSNZ) to encourage urgently-needed public discussion about research, science and 
Technology in New Zealand. It outlines a vision for the future of science in New Zealand. 
Included here are only parts which are relevant to this report. The plan says they have deep 
concern about the careers of students. The public value of science is not being fully 
recognised or realised... science policy over the past decade in New Zealand has resulted in a 
gradual disempowerment of science and scientists. Needed is an energetic and passionately 
practiced science system that is a visible contributor to the nation’s wellbeing; for science to 
be central to the New Zealand identity in the same way that sport is already, and the creative 
arts are becoming. 
“We must, as a nation, use science and scientists better than ever before and find new ways of 
enhancing their contribution.” (NSP-RSNZ, 2008). 
 
3.24.1 How Should This Be Carried Out? – Recommendations from The Science 
Manifesto’ 2007  (NSP-RSNZ, 2008) 
3.24.2 Enhance Innovation Policy 
Have a national policy on innovation which must recognise the critical contributions that 
research, science and Technology (RS&T) each make to innovation. To build innovation-
based economy policies that enhance relationships between the wider business sectors, the 
Crown Research Institutes and universities are needed. Science institutions need to co-operate 
with businesses, not compete with them as they do under current policy. “Excessive 
competition creates barriers to knowledge transfer and a breakdown in trust. Instead we need 
an innovation ecosystem in which intellectual property and new business opportunities flow 
better from primary science organisations to the private sector.” 
 
3.24.3 Ensure that government policy processes are evidence based 
We need to reduce transaction and compliance costs. For many researchers, the current 
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administrative overburden is simply crushing. We must change the way our science is funded 
and make the process less bureaucratic, with lower transaction and compliance costs.  
New Zealand also needs to develop high-quality retrospective science monitoring processes 
involving peer review (NSP-RSNZ, 2008). 
 
3.24.4 Continue to increase both public and private RS&T investment 
Most science funding applications in New Zealand have a failure rate greater than 80%, with 
some, like the Marsden Fund, consistently rejecting over 90% of proposals – not based on the 
quality of the proposal but solely as a consequence of having insufficient funding available. 
New Zealand needs: 
• A deeper pool of research knowledge, ideas and opportunities 
• It needs to retain excellent people and build critical mass. 
• It needs the resources to attract internationally-leading individuals and their teams to 
New Zealand, as Australia and many other nations now do. Critically, it has a very low 
capital investment in research equipment and infrastructure. 
• Needed is a vital culture change to encourage greater private sector research investment. 
Again, less competition with the public sector and more collaboration are needed. “Staff 
must be able to move freely between private and public sectors without compromising 
their careers”  (NSP-RSNZ, 2008). 
 
3.24.5 Improve the path to commercialisation           
Many people have good ideas but they often fail to successfully implement or develope them 
to get them to market. The report says the link between innovation and economic 
transformation must be addressed. Perhaps public research organizations are not equipped or 
funded to take the work to the point where businesses or individuals will invest (NSP-RSNZ, 
2008). 
 
3.24.6 Promote science across the entire education system 
New Zealand needs to at least double its number of science PhD graduates in order to provide 
the human capital needed to drive an internationally competitive knowledge economy (NSP-
RSNZ, 2008). 
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3.24.7 Build national recognition of the value of science 
The application of public and private scientific research underpins the overall health and 
wealth of a nation. Science is not simply about individual achievement. It is a vital factor in 
determining both our nation’s performance in an increasingly competitive world and our 
ultimate survival with respect to the mounting challenges. We must nationally embrace the 
public value of science (NSP-RSNZ, 2008). 
 
3.24.8 Trust science, scientists and scientific institutions 
Promote cooperation rather than competition, and it means assisting scientists’ development, 
particularly early in their careers. We must now demonstrate a determined commitment to 
address these challenges (NSP-RSNZ, 2008). 
 
3.24.9 Key points from above  
• As a nation, New Zealanders should use science and scientists better than ever before 
and find new ways of enhancing their contributions.  
• For many researchers, the current administrative overburden is simply crushing. Science 
policy over the past decade in New Zealand has resulted in a gradual disempowerment 
of science and scientists. 
• Needed is a clear national policy on innovation. 
• Excessive competition creates barriers to knowledge transfer and trust breakdown. 
• New Zealand needs a deeper pool of research knowledge, ideas and opportunities. 
• We must capitalise on scientific and technological knowledge to achieve a competitive 
edge. 
• Science institutions need to co-operate with businesses, not compete with them as they 
do under current policy. 
 
I refer back to the earlier article by Atkinson-Grosjean, (2002) about the Canadian NCE 
experiment where she asks, 
 ‘When the state becomes a partner with academe and industry in privatising research, does it 
make sense to keep distinctions between public and private, basic and applied? Are they 
differences that make no difference? So what if the distinctions are abandoned? 
 This is a challenge to address. How to carry it out is certainly going to be challenging for 
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scientists, lawyers and the organisations they represent. Could answering this question and 
forming a written policy surrounding this topic help New Zealand by opening communication 
amongst New Zealand scientists employed by District Health Boards (DHB) to innovate? I 
suggest it could –or at least help to increase trust between DHB’s and their employees.   
 
3.25 Health Services Planning –Canterbury District Health Board 
The Canterbury District Health Board (CDHB) has started a planning programme (2003) that 
will take a fresh look at all of the health services that it provides and funds. The purpose of 
this programme is to plan Canterbury’s health services for the next ten years and beyond. It is 
expected that this planning may significantly reshape our health services. This may require a 
look at better ways of delivering health services to improve the health of Canterbury people. 
(CDHB, 2003) 
 
A key point to look at: 
• Is the vision statement of District Health Boards too narrow? Will it encompass the 
opportunities for economic growth presented above by the Science panel? Or will it 
focus policy makers and management minds on local health issues to the exclusion of 
what could be small changes in actions to expand New Zealand health to a global 
economic competitive advantage? 
 
3.26 Concluding Comment about the Literature Review 
We have explored different ideas and discovered medical scientists and their organisations in 
several western countries seem beset with similar problems and opportunities. It is surprising 
that organisation and administration issues are globally similar and their evolutions over the 
last two decades follow a similar time line. What we do know is that laboratories and their 
organisations must innovate to survive, owing to the internet and access to new suppliers, 
distributors, technology etc. However, how they innovate is a source of tension and a 
challenge for their leaders. This must be carried out with support from scientists and 
management, and also Government backing, business, and possibly support from the 
taxpayer. There is a warning for New Zealand – innovate and seize opportunities while the 
window is open. Change the way scientists are treated and funded- reduce the amount of 
stifling bureaucracy or fall even lower in OECD ranking. The trust between medical scientists 
and management needs to be positive.  Addison, (1998), in section 3.10 says, “The positive is 
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characterized by mutual trust, informal communication and problem solving, empowerment 
and perceptions of ownership” 
This thinking leads us to the research question… 
 
4.0 The Research Question:  what are the issues that beset New Zealand medical 
laboratory scientists and also medical scientific officers in carrying out successful work? 
The Research design question asks: 
• What knowledge claims am I making as a researcher? 
• What strategies of enquiry will I take to inform my procedure? 
• What data collection and analysis methods will I use? 
 
There are many types of knowledge claim but an interesting paradigm fit for this study and 
because I was initially not sure of what the issues were and what questions to ask, ‘grounded 
theory’ became the obvious choice. Grounded Theory is claimed by some experts to be useful 
for ‘exploratory researchers which this is. No hypotheses were proposed as the questioning 
was carried out to gain information. Literature reviewing was carried out during and after the 
interviewing as an iterative process.  
 
5.0 Research Framework Methodology 
 
5.1 A Qualitative Process Study  
The framework here is qualitative. Empirical data is gathered from interviews rather than 
questionnaires. Interviews allowed open ended questions to probe the participants’ thoughts, 
follow a lead of enquiry, and discover what scientists wanted to say.  
Creswell (2003), p183, provides some characteristics of Qualitative Research (QR)   
The research takes place in the natural setting... this research mostly took place at the 
participant’s work place. It uses various interactive and humanistic research approaches to 
involve active participation by participants. Data collection for this study was by face to face 
interview. 
Qualitative research is emergent rather than prefigured. I quickly discovered my questions 
needed to change and be refined as I started to ask questions. For example, initially I intended 
having Medical Laboratory Scientists as the only participants and started with a line of 
questioning for them but I immediately found the Research Scientists volunteered other 
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important things to say.  It is best to let the unfolding theory dictate the method. 
It is basically interpretative. I recorded participant’s thoughts in their setting, analysed the 
data for the themes or categories and then interpreted these by drawing conclusions about the 
meaning both personally and theoretically. 
It views social phenomena holistically…an initial driver for embarking on a study might 
include strong personal bias and in my case I found some bias dissipated as the holistic 
picture emerged. Instead of unhealthy bias, my attitudes changed to a genuine desire to 
discover the true picture and propose solutions. I discovered each participant revealed new 
information –but up to a stage when I began to hear the same message, signaling I had 
reached the saturation point. The theory from the literature also helped provide a holistic 
picture. 
Reasoning is complex, multifaceted, iterative, and simultaneous. The reasoning is largely 
inductive but inductive and deductive thinking take place iteratively, cycling back and forth 
from data collection to analysis, to problem formulation and back. This happens while the 
recording, analysing and writing up are taking place.  
A qualitative researcher adopts one or more strategies of inquiry as a guide so to help design 
my questions, I considered several including the Advisory/ Participatory paradigm. The 
method I use is Grounded Theory.  
 
An important point I wish to highlight, is that it is also a process study. By process, I take Van 
de Ven’s (1992) 3rd definition, and from Chia and Langley (2004), who say process involves 
considering phenomena dynamically in terms of movement, activity, events, change and 
temporal evolution. By focusing on ‘something that people do’ (Whittington, Jarzbkowski, 
Johnston et al, cited in Langley 2007), we take a ‘strategy in practice’ perspective which adds 
a focus on micro level activities and practices. However, Langley’s perspective, which I also 
show in this dissertation, aims to apply temporally evolving phenomena at a variety of levels 
such as the individual, organisational, sector and issues related to strategy content. We are 
certainly looking at non linear effects under complexity. For example there are political 
negotiations, and the possible destruction of organisational cultures and activity systems. 
Variance based process theories, while useful, tend to ignore complexity. (Barney, 2001; 
Langley, 2007) 
A problem with attempting this qualitative process research is that parsimony is sacrificed and 
because of scope and time constraints; interviews were restricted to one regional area of New 
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Zealand. I also agree with Weick (1989), that whatever strategy is used, there will always be 
an uncodifiable step that relies on the insight of the researcher. Finally, while some process 
researchers have emphasized the importance of relating processes to outcomes, we should 
remember that “outcomes” are often rather artificial staging points amid never-ending 
processes and can be analysed as such (Langley, 2007). Perhaps a popular lay version of this 
is’ ‘the solution to one problem is often the cause of the next’ 
 
 
5.2 What Is Grounded Theory (GT), And Why I Use It for This Study 
Grounded Theory (GT) methodology emerged from doing research on dying patients in 1967. 
It is a research method developing theory from data instead of from predetermined 
hypotheses. As researcher I begin with data from the interviews or elsewhere and 
progressively develop more abstract categories which integrate and explain the data and 
organise the relationships within them. There are varying interpretations of GT amongst 
scholars. I think this is because the original has been adapted and one of the original authors, 
Glaser, has many refutations and criticisms of how others have misunderstood him. Creswell 
(2003), says GT is an inductive approach moving from the specific to the more general as far 
as understandings; categories and theory are developed directly from the data, rather than by 
approaching the data with predefined hypotheses or constructs to test. Next, as analysis 
progresses the researcher tries to develop understanding and hypotheses as to what is going 
on. These ideas are then tested deductively through more data collection and analysis. So, 
doing grounded theory means carrying out inductive and deductive thinking throughout the 
process. The whole process is iterative and it also relies on an uncodifiable intuitive step by 
the researcher to interpret and make the data become useful information. 
It was discovered, not invented, 40 years ago by Glaser & Straus, who complained that much 
of the research in the 1960’s was verification of theory or development of theory through 
logical deduction rather than from experimental data itself (Glaser & Strauss, 1967). Their 
claim was researchers were using logical deduction from past studies too much rather than 
building new theory from qualitative data. They thought it better to approach field 
observations without preconceived theories and to let the data speak for itself.  
 
Much Grounded Theory (GT) interviewing, according to Glaser, involves passive listening. 
This is followed later, during theoretical sampling, by focused questions to other participants 
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which are based on emergent categories (Glaser & with-the-assistance-of-Judith-Holton, 
2004). I thought this way of interviewing, listening then prodding with new questions was 
worthwhile as more was discovered than expected. Some participants were quiet at first and 
had little to say, and then as the interview neared the end they become animated with ideas. 
As interviewer, I initially did not know what questions to ask or what hypothesis to test. This 
is why my initial research proposal changed so much as the themes were revealed. 
 
GT is a perspective based methodology and peoples’ perspectives vary. My participants had 
multiple perspectives. The GT researcher raises these perspectives to the abstract level of 
conceptualisation hoping to see the underlying patterns which are yet other perspectives. 
Perhaps it happens to the participant firstly at a basic level simply because they are being 
listened to.  
Some of the early points raised during the interview were not answered immediately but only 
spontaneously later in the interview as rapport was strengthened. Everyone had intelligent 
thoughts and opinions about their work, the organisation and politics. As interviewer, I tried 
to find out the degree to which their thoughts and opinions affected the performance of 
themselves and others. Each participant was told at the beginning of the interview that there 
was no right or wrong answer and that I was interested in their own opinion. They were told 
the results were confidential and others would not necessarily know I had spoken with them. 
They were asked not to tell others they had been interviewed and they would not be identified 
in the results. They were also made aware of my qualitative enquiry approach and that the 
grounded theory ideology meant I would possibly refine data, and ask their opinions again as 
the study progressed. As mentioned earlier, we try to look at a situation with a blank slate. It 
is perhaps impossible to approach a problem without bias, which brings the discussion to the 
subject of honesty in research. 
 
5.3 Honesty in Research 
Abraham Lincoln reportedly said, "You can fool all the people some of the time, and some of 
the people all of the time, but you cannot fool all the people all of the time."  
So what about fooling ourselves? Care is needed in order to answer the questions in the search 
for answers to problem and evaluation with our theoretical models, that we do not fool 
ourselves. Interviewer bias should be acknowledged, but in the original 1967 grounded 
theory, it was proposed that a situation be looked at with a blank slate. Some scholars disagree 
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with this, claiming it is impossible to approach a problem without bias. A salesperson needs 
to be biased to believing her product and company are the best. This is biased objectivity. On 
the other hand, it is important for the salesperson to retain integrity and honesty. But even this 
opinion and a business person’s actions can be blinded by bias as to what is truly honest.  
 
5.4 Participant-Personal Data 
Participants in this study are homogenous to the extent they are all medical scientists in one 
region. This has the advantage of keeping to a minimum the many alternative explanations for 
developmental process. So being able to compare cases that are similar in as many ways as 
possible, facilitates deciding whether the change processes are due to transient effects or more 
basic developmental models, but it does not control for cohort effects. A homogenous sample 
of scientists in the medical field facilitates the study of precise, focused questions or 
hypotheses (Van de Ven, 2007). 
 
Before looking at the themes it is helpful to look at the various groups and types of medical 
scientists and how they are funded. Table 1 shows the various laboratory departments under a 
typical main regional health laboratory. Some of the participants interviewed worked in these 
areas. 
 
Anatomical Pathology Department Haematology Department  
 
Cytology  Core Haematology 
 
Histology  Specialist Haematology and Haemostasis 
 
Electron Microscopy  Surface Markers 
  Cytogenetics 
Biochemistry Department    
 Automated Biochemistry Microbiology Department 
 Immunology  Bacteriology 
 Molecular Pathology  Virology 
 Protein Chemistry  Serology  
 Specialist Biochemistry   
 Steroid and Immunobiochemistry National Measles Laboratory 
 Toxicology   
     
Endocrinology Point of Care Testing 
  
Table1  Specialist Laboratories  
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Other participants were employed by the New Zealand Blood service or under some of the 
University departments of pathology and departments of medicine that are listed in Table 2. 
For each hospital laboratory, and also some of the university departments, there are both 
medical laboratory scientists and scientific officers. They are funded in 4 main ways; either 
completely by hospital laboratory, by New Zealand Blood Service, by University, or by a 
mixture of Hospital laboratory and University/research organisations. The age range of 
participants was from 23 to 66. The average age was 50 and the median age was 49. Of the 35 
participants, 34% were female and 66% were male. 
 
 
 
Department of Pathology  
Angiogenesis Research Group, Betaines Research Group, Cancer Genetics Research Group, Canterbury Cancer 
Network, Carney Centre for Pharmacogenetics, Free Radical Research Group, Gene Structure and Function 
Laboratory, Haematology Research Group, Liver Sieve Research Team, Retinoblastoma Diagnostics 
Department of Medicine 
Canterbury Respiratory Research Group, Christchurch Cardioendocrine Research, Clinical Pharmacology 
Research Group,  Eye Movement Research, Health Care of the Elderly 
NZ Multiple Sclerosis Study Group 
Van der Veer Institute for Parkinson's & Brain Research  
                                         Table 2 University Departments 
 
 
                            
                             
5.4.1 Demographic data  
In total, there are over 1600 Medical Laboratory Scientists & Scientific officers employed in 
hospital and community laboratories throughout New Zealand (Massey-University, 2008). 
There are thought to be less than 80 medical scientific officers in District Health Boards in 
New Zealand. This does not include physicists or radiation scientists (P Elder, personal 
communication, Nov 12, 2008). (P Elder was not a participant for this study.) The 
significance of this is that about 20% of New Zealand’s medical scientific officers were 
interviewed for this study. This study does not include physicists or radiation scientists.  
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6.0 Results and Analysis: 
6.1 Summary of Themes to Have Emerged From Interviews 
 
1. What works well now?  
2. New Zealand compares poorly with other countries for funding research and 
development.  
3. Scientists need to be much more pro-active as knowledge providers. 
4. Scientists need to improve public awareness of new discoveries and relevance and 
importance to health and or the economy.  
5. What funding issues are there?  
6. Government barriers for scientific officers. 
7. How medics could make a difference.   
8. Management issues for scientific officers. 
9. Barriers and concerns: medical laboratory scientists. 
 
Note there is quite a bit of crossover of issues in the 9 themes. 
 
6.1.0 Theme 1: what works well now? 
One hospital group and some of the university groups were outstanding in enthusiasm for 
their work and regard for team members and their group management. The enthusiasm was 
exceptionally high compared with other groups. However, caution in comparing groups is 
needed because not all of the university research groups were interviewed. It is possible 
scientists in these groups could be equally enthused and have high regard for their 
management. 
 It was notable that the MLSs and MSOs had high regard and access to their senior scientific 
and clinical leaders. There was a congenial working group. 
The interviewees in one hospital group who worked closely with a university group provided 
very positive comments such as: 
 ‘Our group works well with a flat management structure which means a group of us, 
scientists meet over lunch with our manager and we keep minutes to satisfy IANS for 
documentation’. 
‘It’s a very good system here with our hospital lab and a university research group working 
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together. I do very little admin – we have a manager and a clerical worker to help- most is 
done by them’. 
 
Some comments on what they thought could be helpful to other groups included: 
 ‘Our group is very fortunate as we have research and hospital work and other departments 
should be doing this’. 
‘We don’t look for grants - we have enough ideas here to do research but it’s possibly not 
encouraged or given financial backing in other areas –comes down to individual scientist. 
Managers need to suggest ideas –if publishing is not happening enough it comes down to the 
whole group not doing enough –this is the whole idea of the quality group we have in our 
section. 
 
Some positive remarks about their group culture were: 
‘Scientists are responsible people –we work in a small lab which is very responsible – we 
depend on the culture and individuals –we are responsible to the Clinical Director’. ‘Our 
group has very tight collaboration and we are tightly integrated with school of medicine –
others don’t. Hospital and Government needs to promote collaboration with private and or 
other groups such as School of Medicine’. 
 
Overall, the groups which had close access to their Clinical Director were the happiest.  
In most cases participants thought their laboratory was highly regarded by world standards. 
This suggests a good brand image. Older scientists attributed this to foresight of excellent 
Clinical Directors decades ago. They claimed their lab had an international reputation around 
the world but the public did not have a clue about that.  
The happiest scientists were ones who were challenged, but some, especially MLSs were 
feeling some degree of stress which they believed impacted negatively on their organisation.  
Clinical Directors were well respected for academic ability and were generally good to deal 
with. Section heads in the laboratories were also generally appreciated and some participants 
thought the section head pay was poor for the work load in some areas. Participants spoke 
positively of their peers. 
Some scientists published a lot and participants thought this brought high regard to their 
organisation. They said that as a result of the Government’s need to know how money is 
spent, a lot of bureaucracy is caused. However, a plus for New Zealand Health bureaucracy 
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was made by one senior person: 
‘However it is probably better in New Zealand as the District Health Boards have  a fair bit 
of control and the government distances itself, so we may be unique in the world’.  
 
 
6.1.1 What Works Well Now Specifically for Medical Laboratory Scientists 
 
Medical Laboratory scientists generally thought well of their section heads. On the whole, 
MLS staff relations were good. MLSs spoke positively of their peers. Medical Laboratory 
scientists enjoyed good opportunity for ongoing training. ‘We are able to give conference 
talks and have good communication with colleagues from other labs –this is totally dependent 
on manager’s personality and ego’.  
‘The prime advantage of doing research in a hospital is that we have intelligent medics 
(clinicians) who need a challenge and this would keep them in the country- this would 
encourage people to do research and if they do it this makes them at the forefront of their 
field. This also benefits patients as they get better treatment and the chance to get the drugs 
years before they might otherwise become available’. 
 
The business development group was achieving success in bringing work to the Health 
Laboratory. Participants were pleased with this (although not with the lack of staff to cater for 
the extra workload.)  
 
Overall, MLS participants were much less concerned with funding or politics than were 
scientific officers. However, most thought there were too many middle managers. 
‘Our section heads are great –I only get told about other sections from outside. – with 
laboratory work we get immediate results and feedback’ 
‘Line manager is good at delegating because it’s a big section; delegating helps give delegees 
a sense of ownership’ 
 
One MLS said that management is ok and  ‘the business manager is looking at more space for 
us as we are crammed and work load has risen dramatically because of the new system of 
technology and marketing success’ 
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Another remarked that management seem to be heading the right way to improve, as instead 
of going to private labs, the private labs are coming to us and that private labs have less work. 
‘We have good management relations –they are aware of our problems with lack of space and 
lack of staff –we as well as DHB management want to introduce lean methods to look at 
constraints and what’s holding us up to become better’. 
 
MLS participants who reported directly to the clinical director were more satisfied than those 
who had middle managers. Comments included: 
 ‘Our department is ok as we report to clinical director and patients are first. Too many 
middle managers in hospital though’ 
‘I’m lucky as I have a good boss who is a clinical director of high profile’ 
 ‘Our Medical Director’s goal is to make us a centre of excellence –I can work with him 
because he says what he is thinking –he is encouraging toward publishing’ 
‘ Management has improved in 6 years and are now less autocratic –we now have less 
paperwork –have good dealings with them –they are receptive to improvement –have listened 
to some changes I have suggested’ 
 
Another MLS explained that a major advantage their group had is, ‘we have no middle 
managers but we work under clinical director which is not possible for some larger groups’ 
A manager in one lab confidently remarked, ‘Our group is very fortunate as we have research 
and hospital work and other departments should be doing this’ 
 
Overall medical laboratory scientists were not concerned about top management and some 
were unaware what top management actually did. 
‘Difficult to say what management are doing but they appear to be moving in the right 
direction’. 
‘I’m happy with things as is- but young students could find not enough challenge- About the 
management, doesn’t matter to me- not concerned –not directly affected’. 
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6.1.2 What works well now -Union representatives 
Most participants saw the contribution of the union representatives as valuable. Several staff 
had found the union representatives very helpful and an asset to the organisation. Some were 
concerned the union rep was undervalued and discriminated against by management. 
‘Our union rep boosts morale and has done a great job for us but the management see him as 
a nuisance –our union rep does a great job- is severely curtailed but he does the job because 
he has a passion for staff – union reps are  a great resource’. The medical workers union rep 
is very helpful.’ 
 
6.2 Theme 2: New Zealand Compares Poorly With Other Countries For Funding 
Research And Development.  
There were very strong feelings about this from most of the research scientists. One very 
senior person remarked that if a research scientist made it in New Zealand, they could succeed 
anywhere ‘as funding is so cut throat and hard compared with some other countries’.  
Participants were concerned, and well aware New Zealand invested comparatively less to 
Research & Development than most other OECD countries. One participant remarked that 
this was crazy because we needed investment in innovation because it led to results. 
‘Not doing pure science is short-sighted but Government says we can take research results 
from others. This is crap. We need to include pure science as well as applied for best results. 
Target of Government is for getting employment rather than investing in research’. 
One young post graduate PhD said, ‘It is not always possible to get funding from here so 
PhD’s go overseas and stay and none come back’.  
 
Several participants highlighted the point that without R&D and any infrastructure or 
Research atmosphere at multiple levels in New Zealand, people won’t go to university to do 
science. The top flight people interested in science will go elsewhere. As an example, in 
hospitals, the top doctors won’t come to New Zealand because they cannot get funding. 
 
 It was mentioned more than once by senior research scientists that there were good reasons 
for getting funding by not only government and local organisations, but by overseas 
investments. However, Government put up barriers to this and Pharmac was cited as one 
barrier. Ironically, the Ministry of Research, Science and Technology was another. 
Several comments indicated the need for scientists to speak up and be more proactive in 
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keeping government informed. Several said that Scientists needed to be more political.  
‘Government Ministry is not really aware of the need to support us. Research funds are not 
indexed but go into funding salary increases to keep up with cost of living index only’. 
 Again it depends on the political driver –for example heart research is high and others are 
lower’. 
 
6.3 Theme 3: Scientists Need To Be Much More Pro-Active about promoting themselves 
to government. 
Several participants said scientists need to individually and collectively lobby Government 
and Management. This is to make the scientists heard and to get across the importance and 
value of medical science and research to New Zealand. They believe Government and 
management are not taking enough notice of them. Here is what some Scientific Officers say: 
‘Government need  more input from us as a group to show what we are doing in the way of 
teaching and maintaining standard of work as we offer a specialist service’. 
‘It is our fault that we have not spoken up enough and conveyed our concern’. 
The universities also came in for criticism by senior researchers. ‘The university management 
support are not supporting properly as they need to listen to what we need rather than being 
dictated to from above. The Crown Research and Foundation are adept at slotting in with 
what government says it wants, but where does Government get its info –Crown Research 
Institutes are good at telling Government what we need to do and this is where university 
misses out –university are trying but are way behind’.  ‘Pressure has to go on government –
scientists need to drive this but it must come from both’. 
One scientist with a dual role of hospital and research work thoughtfully posited, 
 ‘I think its time to show that management needs to listen to scientists –everything being equal 
both scientist and management need to challenge each other’. 
A top level business laboratory manager stated that Scientists and technicians need to 
challenge everything such as what and how they do things –‘as a group they don’t sell 
themselves very well and labs tend to be silent services and they need to be more outgoing’.  
Over half of the Laboratory scientists dully remarked that Medical laboratory Science was not 
a very recognised profession as they worked in the background and they had indifferent 
esteem.  ‘People don’t appreciate what we do’. 
 
6.4 Theme 4: Scientists Need To Improve Public Awareness  
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A remark which came up several times was that the general public have a perception that 
science research is not important for New Zealand. The participants blamed scientists 
themselves as a group because they have not expressed ideas. Feedback here was along the 
line of: 
‘Media can help influence private grants and donations’. 
‘Public perception may affect Government response but it doesn’t help change the work –
politicians are not scientifically literate’. 
‘There is a distrust of academics and this is not unique to N.Z.  
‘Scientists are our own worst enemies as we don’t publish to popular media and we have a 
responsibility to publish responsibly but this doesn’t happen –trouble is the media sex things 
up and everything gets blown out of proportion’. 
As can be seen, there was acknowledgement that better public awareness was needed, but 
none were sure how to effectively do this.  
 
6.5 Theme 5: What Funding Issues Are There?  
Comments here were very strong, with a sense of despair over the funding system. Funding of 
course affects every aspect. Funding had implications for work and poor tenure made the 
future of science as a career unattractive. A pertinent comment was that for medical scientists 
employed by district health boards, any extra money the boards got from government would 
go to nurses and doctors first.  
 
6.5.1 Time wasted applying for funding 
A participant said there was too much time applying for research grants -10% time applying –
grants are under funded –only 10% granted from Marsden and 15% from HRC that means 
85% waste. 
‘There is not funding for us to do our proposals which can take 2months –this eats into 
research time’. 
‘Government needs to get serious in terms of where they get money. It is too short sighted –
overseas countries will invest in Pure Research but New Zealand won’t’. 
 
When it was queried whether the proposals were written as effectively as they could to 
persuade the funding assessors the reply was, ‘Our team are very experienced and put in well 
written grants and the grants have 3-4 reviewers who rate it  for particular political driver 
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criteria –this is a ridiculous amount of time for us. How do the assessors know the value of 
the research and what benefits might accrue form it?’ 
 
6.5.2 Better Tenure needed 
The strain on participants of short tenure for their research was obvious.  They needed better 
tenure –the 1-3 year grants did not give them a career. 
Several senior participants explained that Research is not a good vocation for the young as 
there is no money and it’s insecure and that the biggest strain on scientists is the lack of tenure 
and consequentially time spent on grant applications’.  
One said they have seen young bright people go into finance instead, because of poor job 
prospects and long term job security would advice bright young people interested in research 
to go into medicine first and get a vocation before doing research. 
However, some seemed to appreciate that it was not just a government responsibility. They 
were not sure if we can blame Government but said the young are not choosing science 
because it is insecure and we need government backing. 
 
6.5.3 Why purchasing research will not work 
Some politicians want to purchase or capitalise on research from overseas instead of doing the 
pure research here. Politicians and the public seem to think this is the obvious choice for pure 
research here. It is also reflected in the ‘accountability’ or ‘outcome science’ getting most of 
the funding. One scientist frustratingly exclaimed, ‘I am angry at having to promise to 
account and state what will be achieved at milestones, or contract to produce results, and 
annoyed that science journals in our area want to publish pure or research hypotheses but we 
only get funds for practical science’ Funding was judged by how much and in what journals 
their work was published. It was catch 22 for this scientific department. However, most 
participants said most of their work eventually got published but the process took time and the 
more prestigious journals attracted better funding points. 
 
A very experienced participant said, ‘If we don’t have pure or applied research it would be 
like fishing in muddy water with only being able to see the fish a foot ahead. If we are already 
up to date in the field we can see ahead a long way and discover opportunities we may not 
otherwise see. If we rely on overseas research to give us ideas for applied results we will 
always be fishing in muddy water not knowing where to look and catch’. 
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They thought that bringing in research from overseas is a naive political idea as they all do 
this anyway as part of any research. 
‘Purchasing science is crap’, exclaimed another. This remark was indicative of the frustration 
of the research scientists as a whole. 
 
6.5.4 Is the Government behaving like a spoil brat? 
 ‘New Zealand biomedical science has survived in spite of government but the government is 
behaving like a spoiled brat wanting products now’, remarked one research scientist, who 
then said, ‘New Zealand needs an attitudinal shift toward medical science and to write off 
$200m a year for the next 5 years on innovative research and development’. 
 
6.5.5 Funding criteria and publishing research to get funds 
 What criteria are needed to get funding and what does someone who is not a scientist in one 
specialist area know or determine why someone should get funds? 
 A remark was ‘Funding is too targeted.  Crown Research and Foundation are adept at 
slotting in with what government says it wants but where does Government get its 
information? Another said, ‘How do the assessors know the value of the research and what 
benefits might accrue form it?  
‘We have to produce results that, say, benefit the Maoris and other politically correct stuff’. 
(To gain a better funding outcome)  
 
One scientist explained that for the gold publication standard, New Zealand has the lowest 
cost to publish at about $70,000 to produce a paper. In some countries it is double that. Also 
in other countries with larger populations the private sectors pick up the slack –we are too 
small. Finland was given as an example of how strongly and supportive their Government 
backing was. New Zealand with a small population only 20% less than Finland therefore 
needs an attitudinal shift and to write off $200m a year for the next 5 years. ‘At a micro level, 
the Chancellor of Auckland University has been prepared to ‘blow’ IP with the belief they 
may at least get the benefit of some success out of it’. 
 
There was concern that the outcome from the Government can change depending on the 
current buss word. An interesting comment that deserves debate was, ‘The Crown Research 
Institutes keep in house ideas they develop using government money, but this is tied up and 
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the public end up paying again –they have a commercial business model –no ‘public good’ 
science is being done and public end up paying twice when they get to use the science’. 
 
An interesting point about distribution of HRC money was, ‘I resent the fact Public Health 
Research is funded by HRC. This should be, and is the responsibility of the Ministry of 
Health! MoRST have their own minister and budget and they only need to go to one place. 
The HRC needs to go to 2 ministers which is B**y stupid as they should only need to go to 
one place’. 
 
Some participants pointed out the different ways they were funded and how this affected their 
work. ‘There is a gap as some of the work we do for the District Health Board science is 
funded differently so some don’t need as much publishing to get funds or have as much need 
to.    
‘About funding, soft money goes to haematology but no one gives to microbiology’.  
 
6.5.6 More on funding for pure and applied medical science research 
All scientists that were asked about this area seemed to agree with one participant’s remark 
that, government have obsession with objectives or translational science to give funding but 
we must have more pure science and we must have people aware of base and able to see 
applications from that. ‘The HRC is good to deal with –the science system is over managed in 
attempting to direct outcomes and  they don’t understand the nature of serendipity –they 
should give more funds to motivated people -there are not enough funds for pure science –
funding is too targeted’. 
 
 A pertinent point about training was that most economic benefits will come out of the 
researchers own work. ‘ we can’t train scientists if they are locked into one area of doing 
things –we need freedom rather than only having to show benefits as scientifically we don’t 
always know what we might discover’. 
 
6.5.7 PHARMAC -a help or a hindrance? 
PHARMAC (the Pharmaceutical Management Agency) is the part of the New Zealand 
Medicines System that works to ensure New Zealanders have affordable access to medicines, 
and that they use those medicines optimally.  
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However, while some scientists appreciated Pharmac saved the country a lot of money there 
was a problem side to this. One said, that Pharmac save the country heaps but it stops 
overseas drug companies investing here and with New Zealand scientists so patients miss out 
on getting new drugs earlier and top medics are not given their ‘toys’ to keep them in the 
country.  
Several others said that we need to get rid of Pharmac. 
 
6.5.8 The consequences of lack of funding for scientific offers 
This is deeply concerning scientific officers. Older scientists were disturbed that their 
laboratory would lose the ability to carry out in house research and development work 
because of a financial squeeze which in the long run would make it hard if not impossible for 
the Hospital laboratories future scientific officers to regain lost knowledge. This is what they 
say: 
‘Without R&D and any infrastructure or Research atmosphere at multiple levels in New 
Zealand, people won’t go to university to do science. The top flight people interested in 
science will go elsewhere. As an example, in hospitals, the top doctors won’t come to NS 
because they cannot get funding’.  
Research scientists were very concerned at the District Health Boards cut back on scientific 
officers.  ‘Long term development comes from scientists so if cut backs are caused by lack of 
finance or if District Health Boards have Government squeeze, the short term gain in 
employing fewer of us will ultimately make future progress suffer’. 
 
A very serious concern was outlined by some scientific officer participants that our district 
health laboratory wants to reduce the number of scientific officers but in 10 years most of the 
senior ones will have retired anyway. –who will do the development that is expected of the 
PhD and masters type scientists? –the Medical laboratory scientists won’t have time and will 
they have the rigorous training and ability that comes with the extra study years? Scientists do 
more method development and pass it down. 
One suggestion was that maybe the competition grant money model is not good as short term 
nature needs to change –perhaps instead of cutting funding they should only cut half –a grant 
of 1-2 years was too short. 
A problem with collaboration was that if collaborating with say the university or others, they 
take 11.5% overhead which inflates the budget.  
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A business manager said, they were reaching a point where lab service is limited by 
Government but Government funding is flattening out so if we introduce new tests some will 
eventually need to be funded by user pays.  
Another senior scientist said, ‘The system needs more money –there is not enough change to 
system but  if there is not enough change it can’t be done. –Government could help by funding 
the ‘Gap’ to trainees on site and bring in replacements’  
A comment reflecting the perceived value of medical scientists, was that if District Health 
Boards had more money it would go to nurses and Drs, but not to scientific work.  The same 
person said the Government needs to get serious about where they will get money. ‘We could 
do a lot more if we had money’. 
A few scientific officers claimed they had had the odd issue with unfair treatment of their 
budget by superiors. 
 
6.6 Theme 6: Scientific Officers: Government Barriers  
6.6.1 Government Bureaucratic problems:  
Some comments are repeated here from earlier sections. 
One manager remarked that managers were too busy with meetings and paperwork required 
for government bureaucracy. 
‘Government looks for short term benefit but scientists need a longer term’. 
‘There is too much red tape – too much time applying for research grants - Grant system is 
too competitive and difficult –they have obsession with objectives or translational science to 
give funding but we must have more pure science and we must have people aware of base and 
able to see applications from that’. (All research participants made similar comments.)  
 
6.6.2 The effect of improved Quality checks and more computer power 
All scientific officers thought they had more bureaucracy or paper work to do. ‘The new 
system created a bizarre paradox as others used to do it for us but now we have to do the 
compliance work ourselves although there are now more people involved –applying for 
grants has more people in the research offices in both University and support services but we 
have to do more work than we used to’.  
 
6.6.3 There is a drive to innovate but is it misguided? 
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 ‘The CRI’s (Crown Research Institutes)  keep in house ideas they develop using government 
money, but this is tied up and the public end up paying again –they have a commercial 
business model –no public good science is being done and the public end up paying twice 
when they get to use the science. –yes there is a drive to innovate but there is not enough 
investment in the background science or technology’. 
 
6.6.4 Legislation  
‘There is too much marginal time consuming legislation e.g. dangerous goods –blocks us 
from seeing real things or degree of importance’. 
 
6.7 Theme 7: How Medics (Clinicians) Could Make a Difference   
The points raised here appeared to be very important as Medical doctors had more authority to 
authorize and or influence the work for the laboratory. ‘Medical doctors need to tell us what 
will have a future for us to develop and more consideration to this should be given by the 
medical doctors’. 
‘There is no short term or medium term or long term development – development is ad hoc’. 
A comment for consideration was that projects such as assays get developed then die –‘we 
need to identify the projects that will be useful for us to further develop and not waste time on 
developing things that can already be done quickly and efficiently already in Australia. - we 
need to improve and develop new tests and methodology and medical directors need to tell us 
what will have a future for us to develop’. 
However, a senior hospital clinical director who was not a participant in this study, told me of 
their frustration at being blocked by peers and the difficulties their department had from 
shortage of staff and funds. ‘I just wish **** (the general manager) would get up out of their 
chair and come and talk to me rather than send emails’. This supports the empirical findings 
in this study that although the manager may not be able to solve the clinician’s problems, the 
clinician still valued a personal meeting or for a more congenial management. 
 
6.8 Theme 8:  Scientific Officers: Management Issues 
All scientific officers raised concern over management. Caution is needed here. This is not 
intended as an attack on the integrity of a select group of existing managers within a particular 
district health laboratory or health board. Some participants indicated the issues with 
management were common to others at a national and global level.  
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Earlier it was recorded that a senior research participant said the New Zealand district health 
boards and laboratories were given more freedom by the government than some other 
countries. I interpreted much of the frustration as being aimed at successive management and 
management as a profession. However, this does not excuse existing management from taking 
these comments on board and acting to improve the situation. One manager remarked strongly 
that ‘some of them (MSOs) haven’t published anything for years’. This manager was 
acknowledging or suggesting they lacked motivation to publish and get more funding. When 
this was suggested as a problem to participants, the response evoked strong and very useful 
data.  Here are some comments:  
 
‘Lack of publishing is probably the result of bad management –they need to tell us what they 
expect and give us the resources’ –its bad communication – we could make time if we knew 
what priorities were –perhaps they could pay bonuses for published work –to publish one 
needs to be driven –journals change’. 
 
More than 80% of participants commented on lack of management caring. This seemed so 
serious I quote them as such: 
‘My impression is Management only care about their agenda but say ‘we don’t care about 
your agenda’ 
‘Human resources or management shows no sympathy whatever. They probably consider us a 
blot on the landscape –we are tolerated because we (our group) bring in money’. 
‘If you have a good idea and tell management it will be the death knell for it –it is better to 
get on with it –some opportunities are given but the Health Board patent and then the whole 
thing slows down and gets bogged down’. 
 ‘District Health Board management as a whole has had a benign neglect for scientists’.  
‘There is a barrier between management and scientists’. 
‘It’s hard for Joe blocks the scientist to be bad –management doesn’t care –only care about 
their bonuses. Management not really interested –don’t care –futile. H.R. doesn’t care. 
‘Management has not allowed some scientists the climate or environment to publish’. 
‘We are pulled down by senior persons or management’. 
‘Place thrives on micromanagement –bureaucracy feeds on itself –need to appreciate why’. 
‘Make less demand on the scientist for bureaucratic staff reports so we have more time for 
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science’. 
‘We need more staff’ (on the other hand one respected senior section head said we don’t 
necessarily need more PhD’s but better pathways for them in which to work). 
‘The university management support are not supporting properly as they need to listen to 
what we need rather than being dictated to from above’. 
‘Now we have too many managers and there is no productivity sending memos and having to 
keep our own management documents’. 
‘Get rid of managers and red tape otherwise New Zealand will keep failing –they are too 
short sighted. 
‘Management don’t appear to trust or support scientific officers’. 
‘There is a lack of ability of bosses to give good feedback’. (For some participants) 
‘In the process of developing work others up the line can commit people further down the line 
to work without checking to see if the people are in a position to do the work’.  
 
There was some frustration with getting maintenance or equipment when university and 
hospital staff share rooms e.g. One medic having two separate computers in same room 
because the university computer cannot talk to the hospital one, and freezers not getting a 
proper alarm system because of disagreement over who should pay, and in this case the 
consequences, could result in loss of payment from the drug company for research. 
 
 
 
6.9 Theme 10: Barriers and Concerns: Medical Laboratory Scientists 
 
6.9.1 Layers of management 
Generally, the more layers or channels of management between the scientist and the Clinical 
Director, the less job satisfaction Medical Laboratory Scientists had. Conversely, the more 
access MLS participants had to mangers and Clinical directors, the less frustrated they were. 
Comments from participants strongly suggest that scientists want and need managers to be 
proactive in not only asking about work but in socializing with them more. They wanted a 
more congenial management style. 
 
6.9.2 Peer resistance 
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In contrast to many MLS’s who were content to just do their job, several strongly revealed 
their desire to try new things. ‘It is frustrating that some scientific and management staff don’t 
want change to new techniques and they even resist change’. 
‘Peer resistance is possibly slowing progress with new assay methods’. 
 
One participant expressed concern about new techs and scientists as to whether they will 
really understand work - ‘It’s important to go into small areas and new areas for experience’. 
 
6.9.3 Constraints 
A senior MLS manger pointed out that they were constrained by working for the District 
Health Board as the structure did not allow time to develop their own ideas.  They were 
primarily there to serve the patient which constricts some personal science ideas that some 
may wish to develop as the ideas must translate into patient care.  
‘Compliance regulations have us caught and trapped tying us in knots. Now more form filling 
than used to be’. 
One remarked that they thought many are going to Australia and it is difficult to get staff. 
However, difficulty getting staff was refuted by a manager. But another participant said, ‘it 
was hard to find staff and management doesn’t believe we need staff’.  
Others felt the pressure, ‘There is so much work pressure and time restrictions make it 
difficult to get staff levels right.  
 
6.9.4 Management issues 
 ‘The management doesn’t have tea with us –they don’t associate with us –they are told to 
keep separate from us. This is current management teaching’. In response to this comment, 
one senior manager said they wished they could have tea with staff but they did not always 
have time.  
A comment from another senior MLS was, ‘Biggest bureaucratic issue is communication and 
management don’t involve people they should –management have difficulty understanding 
basic concepts of what we do and of science –poor communication–however department 
managers are generally very good’. 
‘Team leaders have too much work for their pay level’. 
Even though most were appreciative of line management or section heads, the same 
participants said there were now more channels of management and managers gradually lost 
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touch with the coal face. Also, several commented that the more channels of management, the 
further away they were from clinicians. This complimented the earlier statements under ‘what 
works well now’ heading where it was recorded that staff felt fortunate to report directly to 
clinicians. 
  
‘Oldest staff used to rotate sections but not now and this is a bad thing’. 
 ‘We need more space as we are crammed and work load has risen dramatically because of 
the new system of technology and marketing successes’. 
 ‘Don’t think our boss appreciates what is involved and how much work is done’. 
‘Management should act more on what the coal face say –sometimes they do – they listen but 
don’t act! –This is not acted at the top level by the medical director –it is blocked if money is 
involved!’  
The above comments can be countered with several positive statements by MLS’s that 
management was good.  
 
6.9.5 Encouragement and work feedback 
Several remarked that the union representatives had been very helpful but were unappreciated 
by management. 
 One person said, ‘We don’t get much in the way of congratulations and social info from other 
labs outside.’ Also they thought the pay was pitiful. 
 
A senior MLS expounded that, ‘There are some aspects of people needing to be spoon feed 
but I refuse to do that –the scientific role of people is to expand and push boundaries but I 
don’t think I should be on their backs –they should be more self motivated –how long do you 
spoon feed people?’ 
A respected worker exclaimed ‘Management has no respect for us whatsoever. The managers 
can’t manage – if someone does a bad job the managers don’t come up to the person and say 
‘hey you have done a bad job’ – it’s ignored’.  
 
6.9.6 Human Resources (HR) 
From the overall comments, participants were positively and negatively polarised on the 
helpfulness of HR. Generally, most participants viewed the Human Resource people as 
management pawns. A common remark was, ‘Human resources department are not helpful to 
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workers –too anonymous and don’t have enough presence –they stand back and wait to see 
what happens –to understand legislation they need some science understanding –good on 
protocol but not on details’.  
‘Human resources department are severely handicapped by not having a scientific 
background. –they are not there for staff but only for management’. 
 
There was some appreciation of the ‘rock and a hard place’ position of the HR department. ‘I 
feel sorry for some –depends how well they get on with management –some are excellent and 
some are horrible. HR gets caught between workers and management. Managers forget they 
are working with people’. 
However, one participant commented that ‘Human resources have been personally helpful in 
the past’. Another made quite a point of reporting that the HR person had been excellent 
helping their department. 
‘Human resources are helpful but are under similar stresses’. 
 
6.10 What Do The 10 Themes From The Interviews Tell Us? 
They tell us:  
Facts – An example is that government funding to hospital laboratories is limited. 
 
Inferred data- For example, because some participants say it is very difficult for the 
organisation to get qualified staff and they are overworked, but another participant who is a 
manager says they can get staff if they present a good case to top management, the inferred 
data is that  management will let the staff be overworked because the staff have not made their 
case known, or staff are afraid to speak out, or managers are afraid to present the case for 
more staff, or one of several other points.  
 
Emotive information- Every participant showed degrees of emotion. Some were enthusiastic. 
Some were disillusioned. Others were concerned. A few were angry. Most were appreciative 
and yet for various stages of the interview they displayed any one of the above emotions. 
At the lowest level of abstraction, we get data. Information is the next level, and finally, 
knowledge is the highest level among all three. Information becomes knowledge when we can 
act on this information, either to solve a problem, for example, to motivate a manager to 
spend more time socializing with staff, or to gain insight into an issue such as why some 
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scientists are not publishing enough. (Wikipedia -the free encyclopedia, 2008) 
 
7.0 Recommendations from Analysis and Combining of the Literature Review and 
Empirical Data 
What is significant from the interviews (Section 6.1) is that the team with the least frustrated 
scientists enjoyed close teamwork and participants in this group believed they had a 
comparatively flat management structure with all workers having access to the clinical 
director. While some of these participants in one team were funded by the hospital and 
another team was funded by university, there was some cross funding and a definite co-
operation between workers. Workers shared the same building for most of the time. The two 
groups each had a Medical laboratory scientist as administration manager, who worked 
together when necessary, but who had converse situations to deal with. The MSOs were not 
burdened as much by bureaucratic issues as their counterparts were in other laboratories. 
The university funded team mentioned above was highly regarded by younger participants for 
the team’s work which was seen as a leading world standard. Participants also said the clinical 
team was enthusiastic and the medics world leaders in their field.  
The enthusiasm and approachability of all clinical leaders was acknowledged to be a huge 
factor in motivating MLSs and technicians as well as MSOs. Some participants thought their 
group was very fortunate to have both research and hospital work and that other groups 
should do this. On the other hand, some MSOs in other groups were very frustrated that they 
had too much hospital work which hindered them doing research or publishing. 
The ‘happy’ group had ‘tight collaboration with and were integrated’ into the school of 
medicine, whereas other groups were said not to be. For all laboratory groups, section heads 
were appreciated and participants generally spoke well of their peers. 
 
The results above are similar to the American findings of a study by Sapienza (2004). 
 In her introduction to ‘Managing Scientists’, Sapienza writes that between 1996 and 1999, 
her group surveyed 147 scientists, of whom two-thirds were PhDs, 14% were MDs, 5% were 
PhD-MDs, and the remainder MS technicians (and students). Most were from the life 
sciences, some had doctorates in engineering, mathematics, and physics. A slight majority 
was working in academia, the rest in biotechnology and biomedical companies. These 
scientists provided a window into what it felt like to lead and to be led in scientific endeavors. 
Sapienza says,  
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‘The importance of leaders' care and compassion to scientists and technicians working in the 
laboratory was striking. The best leaders were characterized as scientifically very competent, 
and compassionate and caring deeply for collaborators and subordinates’. 
One respondent in Sapienza’s study noted, the best leader was "caring but assertive”. There 
was good working rapport as well as friendship in the lab, and an overall feeling of 
appreciation for the work done.  Similarly, in contrast to the use of negative reinforcement by 
ineffective leaders, the best leader not only criticized but also praised. “A lot of people tell 
you when you've done something wrong. Very few people tell you when you've done 
something right”.  
However, a comment was made from one participant in my study that ‘no one tells anyone off 
when they have made a bad job.’ 
 Results also suggest workers rated having bosses as ‘nice people’ more highly than scientific 
competence. While Sapienza doubts it could be proved that effective leaders caused good 
science, she asserts that surely with good leadership, more "brain power" can be employed in 
scientific endeavours under effective leadership conditions than under the opposite conditions. 
Consider how difficult it is for people to focus on the science, says Sapienza, if they are 
caught in unresolved conflicts, the crossfire of sniping and negative criticism, or work 
thinking they are not valued or the bureaucratic paperwork is simply to keep the boss and 
their boss in a job.  
 
Consider this in relation to the comments from (6.1.1), clinical directors and the participants 
worked with or for, were well respected for academic ability and were said to be good to deal 
with. In fact older scientists claimed their lab had an international reputation around the world 
but the public did not have a clue about that. The high reputation was attributed to foresight of 
excellent Clinical Directors decades ago. 
 
The importance of clinical directors was pointed out in (3.12), where the Canadian Genetic 
Diseases Network (CGDN) and the effect of the success of the NCE was largely attributed to 
a single most important factor, that being the outstanding leadership of the clinical director. 
Findings show the high importance of excellent clinical leadership and the positive effect on 
having charismatic leadership who inspire teamwork. Findings from my study indicate this 
applies also in New Zealand. 
Consider the statement from an MSO (6.7.0) on how clinical leadership could make a 
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difference. “Medics (medical doctors)  need to tell us what will have a future for us 
(scientists) to develop and more consideration to this should be given by them’. From the 
point of view of this study and the comments from leading scientists in sections (2.1, 3.5, 3.12 
and 3.22), this ranks high in importance. Clinical leaders need to tirelessly advocate their 
cause by inspiring, caring for, and motivating people around them. More money is needed. 
But it is not the entire answer. This study, together with the literature suggests the leaders can 
do a great deal to influence the productive output from the laboratories of New Zealand 
simply by good leadership skills. I would add here that unless the leaders and management 
have a genuine concern for MLS’s and MLO’s, any attempt at introducing programmes for 
motivation may not be effective. The old saying, 
 
 ‘People don’t care how much you know until they know how much you care’ should be taken 
note of. 
 
In contrast to clinical leaders, there is very strong negative criticism of managers and the 
amount of bureaucracy. However, the comment from  6.10.4, ‘Management should act more 
on what the coal face say –sometimes they do – they listen but don’t act! This is not acted on 
at the top level by the medical director – it is blocked if money is involved!’  This shows some 
difficulty managers face. How much more motivated would MLSs and MSOs be, if instead of 
believing the comment from 6.8.1, 
 ‘If you have a good idea and tell management it will be the death knell for it – it is better to 
get on with it – some opportunities are given but the District health Board patent and then the 
whole thing slows down and gets bogged down’, they instead believed they would be taken 
seriously and could not only have a part in carrying out the project, but to even share in the 
financial rewards. Consider this statement, ‘Management don’t appear to trust or support 
scientific officers’, and from another scientist ‘My impression is Management only care about 
their agenda but say ‘we don’t care about your agenda’ 
‘Human resources or management shows no sympathy whatever. They probably consider us a 
blot on the landscape –we are tolerated because we (our group) bring in money’. 
 
Unfortunately, nearly every MSO and some MLS’s had little trust in management. This is not 
necessarily the same as thinking management ‘were doing their best or were improving’. I 
remind readers that the answers from some participants inferred that management possibly 
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included health management in general. As one MSO said ‘trust is not there’.  
 
Returning to the literature section (3.10) and the significance of trust (Addison, 1998), 
showed trust as a ‘prior context’ comprised the building block of change. Positive prior 
context is characterised by mutual trust, informal communication and problem solving, 
empowerment and perception of ownership. The participants in our study did feel some 
empowerment, especially MSOs. The MLS felt less empowered and most MLSs said this was 
because of time constraints, but they were not overly concerned by it. For all MLS 
participants the average results show a slight positive prior context. However it is noted that 
even so, for some MLSs, trust with management was a problem affecting their work. Very 
significantly however, for MSOs there was a strong negative prior context in the area of trust. 
What is so serious about this is that not only do we have frustrated people; the economic 
progress of the Nation may be affected. 
 
Therefore, empirically from my interviews and also the literature results and from Sapienza 
and Addison’s findings, it is clear there is much benefit to be had from both leadership and 
management  taking initiative to become more ‘caring’ and effective and to develop trust.  
Why is there a problem here? Scientists and technicians know managers are well qualified 
and hard working people. They may also believe Gary Hamel (Hamel & with-Bill-Breen, 
2007) one of the world’s top management advisors who writes for Harvard Business Review, 
when he reminds us that most of what we have is the result of management. Hamel says 
“...We should bow at the feet in front of shrines to Daniel McCallum, Frederick Taylor, Max 
Weber, Chester Barnard, and W Edward Deming, Peter Drucker and all the other apostles 
and prophets of modern management”.   
 
During the interviews I had an impression that many participants could be helped by first 
helping themselves – by learning to communicate better –by becoming more assertive –  and 
by studying their own character to see if perhaps they could be part of the ‘problem’. For me 
as researcher, this would have to be the most outstanding lesson I learnt. It was a deep 
privilege to listen to participants. I also saw my own weaknesses reflected in others as I have 
faced work and life issues. I recommend reading Fielder (1993) p155  ‘Does someone at work 
treat you badly?’ The author explains how to handle difficult bosses and co-workers. He says 
that as therapist and seminar leader he has seen very intelligent people plagued by their own 
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harsh ‘Inner Critics’ and these people need to stop being so hard on themselves by asking if 
this self criticism was necessary or useful and would the energy be better spent getting 
support and ideas for solutions. 
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7.1 Theory 
‘The ideas of economists and political philosophers, both when they are right and when they 
are wrong, are more powerful than is commonly understood,” wrote John Maynard Keynes, 
(as cited in Ghoshal, 2005). ‘Practical men, who believe themselves to be quite exempt from 
any intellectual influences are usually the slaves of some defunct economist…It is ideas, not 
vested interests, which are dangerous for good or evil.’ 
The late Sumantra Ghoshal claims this is exactly what happens in management. In courses on 
organisation design, grounded in transaction cost economics the need for tight monitoring and 
people control has been taught - the reason is to prevent opportunistic behavior. Alongside 
this, management students have studied Porter’s five force theory which teaches that 
companies are competing against competitors as well as suppliers, customers, employees, and 
regulators. These ideas have been ingrained into management practice and according to 
Ghoshal, and of great concern; the result has been the delegitimisation of companies as 
institutions and of management as a profession. These theories have affected the way day to 
day decisions are made. 
 
Ghoshal (2005), then argues that academic research related to conduct of business and 
management has had some significant and negative influence on the practice of management 
thereby affecting the world view of mangers. The result has been propagation of amoral 
theories freeing students from any sense of moral responsibility. Business schools have 
extensively adopted the scientific model. There is not room to delve into the fascinating 
background here but it is worth mentioning Hayek’s 1989 Nobel lecture, “The Pretence of 
Knowledge” which says the pretence has demanded theorising based on partialisation of 
analysis, the exclusion of any role for human intentionality or choice, and the use of sharp 
assumptions and deductive reasoning (Bailey& Ford, as cited in Ghoshal, 2005). A 
precondition of making business studies a science has been the denial of any moral or ethics 
in business theory and hence management practice.  
 
Continuing with Ghoshal’s idea, there is a theory called ‘liberalism which is ideology 
grounded in a set of pessimistic assumptions about people and institutions. Hirschman, (as 
cited in Ghoshal, 2005), called this ‘Gloomy vision’ which views social theory as solving 
negative problems of restricting the social cost of arising from human failings. This ‘Gloomy 
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vision’ theory combined with the ‘pretence of knowledge’, set management research headed 
in the direction of making excessive truth claims based on partial analysis and unrealistic and 
biased assumptions, claims Ghoshal. Now according to Gergen (1973), unlike theories in 
physical sciences, theories in social sciences tend to be self fulfilling. Therefore if a 
management theory gains enough attention it will change the behaviour of managers to start 
acting in accordance with the theory. So the theory that assumes people behave 
opportunistically, and draws its conclusions for managing people based on that assumption, 
can induce actions that are likely to enhance opportunistic behaviour among people. I believe 
this is so and can give practical examples from my own work experience. Osterloh and Frey, 
(as cited in Ghoshal, 2005), say that a theory that draws from corporate governance on the 
assumptions that managers cannot be trusted can actually make managers less trustworthy. 
The theory may have been wrong to start with but it becomes right as managers conform their 
behaviour to the doctrine. Ghoshal demonstrates this is precisely what has happened to 
management practice over the last several decades the collective pessimism about managers 
has become the realised pathology in their behaviour.  
 
If business schools have adopted the ‘scientific approach’ this may have given some 
significant benefits but the costs have been high. The methods of physical science can not 
always be applied to business studies. Ghoshal goes on to say that when mangers and CEO’s 
justify their actions by pleading powerlessness in the face of external forces, it is to the 
dehumanisation of practice that they resort. Claims of competition or capital markets being 
relentless and management has no choice, it may be on the strength of false premise of 
determinism that they free themselves from any sense of moral or ethical responsibility. I 
would not go as far as to say this would apply to Hospital or Laboratory management –
although it possibly manifests in other forms - but I suggest Ghoshal’s premise that common 
sense has also suffered a toll, definitely applies to the whole New Zealand Health area 
including the managing of medical scientists. If you do not believe that common sense has 
suffered just reread the participants’ comments from my study. Despite this, it needs to be 
acknowledged here that with medical laboratory and hospital issues, what may appear as 
ridiculous bureaucracy to some workers may actually be essential for safety reasons such as 
infection control.  
There are apparently numerous examples of how the applications of social theories like 
scientific methods, had lead to poor public policy decisions in the United States (Campbell, 
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1988). The academic world, Ghoshal says, needs to acknowledge the serious problems of 
social theory and in particular the issue of management and corporate governance, and to 
rethink these issues and change them.  – For instance, the fact that years of business school 
teaching has resulted in practices that are now loudly condemned. The honest reason 
according to Ghoshal, is because such a perspective cannot be modeled due to such a theory 
being unable to give simple reductionist prescriptions or to easily yield testable propositions. 
As well as this, the math does not work, which results in no protection for the ‘Pretence of 
knowledge’. This would mean that business could not be treated as a science and we would 
have to fall back on the wisdom of common sense. It is interesting that with Ghoshal’s theory 
here about social science and management, I have brought this into the study to consider his 
idea as it might apply to managing a district health laboratory where the workers and indeed 
most managers are scientists. This is not meant to be an attack on laboratory managers, but 
rather it possibly explains how managers can be trapped by their own bosses and or health 
boards and government bureaucrats.  
 
An excellent book, ‘Managing Scientists’ (Sapienza, 2004) and in my view, essential reading 
for all Laboratory managers, was originally written because she believed that effective 
leadership of scientists requires surmounting several difficulties that are different from those 
found in "nonscience" situations. Sapienza, a professor of management, does not agree 
however with some who believe scientists do not need leadership.  
 
Could it be therefore, that the decisions of all of the funding bodies and the government 
minister, to make funding available to applied science where the expected outcomes are stated 
and assessed by people outside of the discipline in which the research is being carried out, is 
actually a fundamental error and lack of common sense for the aforementioned reasons? Is it 
possible the proponents have been brainwashed by ‘physics envy’, and by the ‘boundary 
setters’ defunct economic blindness? I would of course be foolish not to acknowledge that in 
our world of Porters 5 forces and the World Wide Web, accountability and limited finances 
are reality. It just means that the accountability needs to be different, which is where recent 
challenging ideas from respected popular management writers Gary Hamal, Peter Drucker, 
Tom Peters and Robert Grant should be taken notice of.  
Consider Hamel’s (2007) theory from “The Future of Management’ from the chapter on 
Management Myopia. 
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“Strangely, managers are unsurprised when science advances by leaps and bounds, yet seem 
unperturbed when the practice of management fails to do the same.” 
He continues by saying that Management is stuck in a time warp –or have we mastered the 
science of organising human beings?  Management has evolved rapidly in the first half of the 
20th century but now peaked, and the S curve of evolutionary management has matured. 
Hamel boldly punctuates his beliefs with the words, ‘We are at the end of management as we 
know it.’ 
 Hamel also says management has not changed much in 30 years compared to scientific 
progress. In fact management has changed but perhaps in the wrong way? 
 
While there has been strong criticism of Laboratory management, this needs to be balanced 
with the many positive statements. This is particularly so for line mangers. Also of note is the 
senior management experience and qualifications along with obvious drive to make their 
organisation succeed for the benefit of the local area.  It is clear management and scientists 
have been caught in a crippling bureaucratic system and while acknowledged by all, there is 
no quick way out of this unless each manager takes more risk and has the courage to allow 
scientists to carry out research and innovate more on their terms. Administrators and 
politicians need to give scientists the playing field they need. Of course this is risky! But I 
believe the rewards are high. Scientists need flat management with opportunity for technician 
to Research scientist, to innovate if they wish. For any person, from maintenance technician to 
the CEO to block them is cowardice in the face of strong empirical and theoretical demand of 
the philosophy of science. This statement or words embracing the intent should become part 
of the proposed policy of innovation.  
 
Scientists and managers see that the Internet is shifting bargaining power –e.g. some local 
individuals have produced and sold products or biotechnology to Europe. We can compete 
with anyone. It does not take Gary Hamel to point out Strategy life cycles are shrinking. To 
survive we must out-invent, and outthink a growing number of upstarts.  However, we need to 
listen to Hamel (2007), when he blatantly states –‘we don’t need bureaucracies of 
government departments –we can negotiate ourselves directly.’  
 
When confronted with why management has not changed as much as other disciplines, Hamel 
says that the reply is that there are limits, they argue, to the number of people that can be 
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effectively supervised by one person, to the degree to which accountability can be distributed, 
to the extent to which employees can be trusted, to the willingness of individuals to 
subordinate their self-interests to the interests of the corporation as a whole. Hamel believes 
most of these are imaginary excuses which offer managers a soothing alternative to the 
premise that it is a lack of imagination that constrains management innovation. 
My question is, perhaps also that it is not so much a lack of imagination but more to do with 
the way state owned enterprises or health managers are rewarded with high salaries.  
Consider one participants statement, 
“I think when budget cuts are needed the managers cut out research as it is a long time 
before results can be seen- if they can be seen –this way they keep their bonus- tacit 
knowledge of the scientist  is then lost for not doing the research.” 
As well as that, perhaps laboratory management need to stand up to superiors such as the 
CEO of the district health board who may demand for example that ‘no more staff shall be 
added,’ and actually present a case to justify the need for extra staff as a means of bringing in 
extra funding in years to come. 
The only present way up the pay scale is to manage and be accountable to managers higher 
up.  They are trapped - trapped by the Government funding and accountability system and a 
comfortable remuneration, secure in the comfort that the CEO’s of the hospitals to which they 
provide service earn even far more for being their spokesperson and attending meetings and 
Powhiris.  As one scientist put it,  
“There is too much paperwork which is administrative trivia given to justify admin jobs–I 
ignore as much as I can and it goes away – there’s too much duplication of data which is 
available on data bases already. Management can’t think outside the square -management 
feel threatened by staff and put up barriers and get us to fill out forms –they keep separate-
build up their own control and don’t contribute anything meaningful to the organisation.” 
Consider the statement from two participants: “... I’ve noticed in the last 10 years there are 
more middle managers creating more memos and manager ‘speak’ to justify their positions –
this is the New Zealand district health board culture now.”  
“Management doesn’t care –only care about their bonuses- Management not really interested 
–don’t care –futile. Human Resources don’t care. My impression is they only care about their 
agenda but say ‘we don’t care about your agenda’ 
 
Returning now to Hamel (2007), in ‘Management Myopia’, “most managers see themselves 
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as pragmatic doers, not starry-eyed dreamers. In their experience, management progress is 
accretive rather than revolutionary—and they have little reason to believe it could ever be 
otherwise. But it can be otherwise, and it must be—the future demands it.” 
Perhaps management does care? Perhaps they are trapped and too busy with bureaucracy to 
truly help their staff? Likewise, employees in MoRST and other organisations may also be 
trapped with the same problem.  Or perhaps there could be other reasons. Whatever these 
reasons are, if we take Hamel’s beliefs seriously, and we consider the empirical results from 
this study, the current management paradigm of these organisations is obsolete. (I fear to 
make this claim myself but regretfully the study indicates that it is.) The good news is that 
existing management of the laboratories where this study was conducted and who authorized 
this study, are to their credit, high achievers who truly appear to want the best for their 
laboratories. 
 
The other reasons I wish to pursue, have to do with communication. One can take a lesson 
from Chapman and Thomas (2006), authors of  ‘The languages of apology’. We each have a 
language of response. For example when a participant said, ‘We don’t get much in the way of 
congratulations and social info from other labs outside,’ it suggests this person responds well 
to words of affirmation. When another participant said, ‘The management doesn’t have tea 
with us –they don’t associate with us –they are told to keep separate from us- this is current 
management teaching,’ it may also mean this person has a high need for affirmation or 
recognition. On the other hand, some managers have a primary language of ‘works of 
service’. These people don’t need affirmation but show and respond by doing deeds. The 
point Chapman and Thomas make is that we need to appreciate the different ‘love or 
communication’ languages people in the laboratory have. Results from interviews tend to 
suggest we all need to be reminded of the different ways people respond to and benefit from 
affirmation. We are not all the same!  
 
8.0 Summary 
Top points to come out of the data are: 
 
For Scientists 
• Medical scientists need to be much more proactive in informing government, 
management and the public about the value and benefits they can make to New Zealand 
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economy and health. Scientists need to better sell themselves and challenge the status 
quo. 
• Some scientists need to take bolder steps to overcome personal difficulties, e.g. learn how 
to be more assertive and congenial. These are issues common to all people who work in 
teams. 
• Scientists need to see beyond the failings of management and government but work to 
become ‘part of the solution’ rather than blame inadequate management. 
 
For Management 
• There is too much unimportant bureaucracy, much of which is to support managers and 
their bosses. If it is important to managers then the reasons should be explained to 
workers. Some of this bureaucracy hinders scientists and technicians from acting on the 
important issues.  
• A very serious concern was outlined by some scientific officer participants, that our 
district health laboratory wants to reduce the number of scientific officers –who will do 
the development that is expected of the PhD and masters type scientists? –the Medical 
laboratory scientists won’t have time and will they have the rigorous training and ability 
that comes with the extra study years? Scientists do more method development and pass it 
down. District Health boards need to consider this wisely in terms of the long term 
damage reducing medical scientific officers may have. The theory in this dissertation 
supports the need for more scientific officers and to give them more freedom and 
allowance for ‘failure’ but it also demands accountability from them. 
• Managers are caught in too much bureaucracy generated by their own bosses or 
government. Perhaps they need to question their own superiors on the value of this. 
• Scientists and technicians are well qualified and capable of making good decisions. They 
resent being mistrusted by management. Nearly all MSO participants thought 
management did not care and they did not trust management. The result of this is a huge 
waste of human intellect and output. As researcher, I believe there is huge potential for 
economic gain yet to be released by medical scientists and clinicians and although their 
organisation’s management may not be perfect, the potential is there regardless of the 
‘perceived’ lack of funding. 
• Data shows scientists want and need more encouragement and socialising from the 
management. Because managers tend to be ‘power’ or ‘achievement’ orientated this can 
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mean they may overlook the value of socially interacting with others who are ‘affiliation’ 
motivated. Scientists and technicians work better if they feel part of a caring team.  
• Managers should trust scientists and involve them more in decision making where 
appropriate to make them more part of the team. Many scientists had little idea of 
management issues. 
• Both MLSs and MSOs should be given opportunity to develop their ideas but these need 
to be followed up by management at regular intervals to check on progress. Note that 
some world leading innovators such as Dean Kaman and Bill gates did not complete 
university degrees. (Kamen was awarded the USA National Medal of Technology in 2000 
by President Clinton for inventions that have advanced medical care worldwide.) 
• Intellectual property owned by laboratories or funding agencies needs to be acted on and 
individual scientists encouraged to work as a team to bring products to market. At present 
scientists are wary of management. Ideas are ‘locked’ by deep mistrust of management 
and fear of legal and management retribution. 
• Clinical directors need to be asked to provide definite leading and direction for the 
laboratories. Clinical directors need to develop the economic potential of the Medical 
scientist and laboratory and realize they have a part to play in leading economic growth of 
New Zealand as well as working on local health issues. Health Boards and hospital CEOs 
need to allow clinicians more latitude in work which could help the economy rather than 
just local health. There needs to be a much stronger focus on encouragement for clinicians 
wishing to innovate. Within reason, the fear of legal restraint should never stop an 
innovator. 
 
For Government 
• The New Zealand Government has defined direction and we need to be very grateful for 
this. Scientists and the public need to appreciate the work government have done, but the 
government could help by routing out the ‘Tall poppy syndrome’ endemic in New 
Zealand. 
• Organisations like MoRST, who claim they are the best people to tell government what 
needs to happen, should be seriously challenged. There are too many layers of 
bureaucracy with people who are not capable of making correct scientific decisions in 
someone else’s area of expertise. 
• MoRST and other organisations should allow more cross fertilization of biotechnology 
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ideas and not tie up ideas in patents unless they give others within New Zealand 
opportunity to develop or work with the inventors. 
• If the government believes what it says about the importance of medical science as an 
export earner, then it needs to provide much better tenure for researchers. 
• Governments should force health boards and government departments to reduce 
management obstruction and appreciate that workers are more qualified than they used to 
be 20 years ago. 
• Universities and hospital laboratories that share premises need to have a common 
management of buildings and plant, computing etc. Much frustration to scientists is 
caused by duplication of resources but denial of responsibility. Hospital and university 
management need to sort this problem out urgently and make financial savings for both 
institutions. 
• Government need to listen more to medical scientific officers rather than just district 
hospital boards and MoRST.  
 
Final comment 
The New Zealand public has a right and a need to demand action on the issues raised. It needs 
to be emphasised to the minister of health that medical scientists believe there is too much of 
the wrong kind of bureaucracy. 
At a local level, while it is widely acknowledged that more money is needed for medical 
science and that scientists and management of laboratories may be trying to take a global view 
to bring in more work, more trust and management congeniality of their scientific staff is 
needed. As one MSO participant in this study said, 
 
             ‘It is time for scientists and management to challenge each other’ 
 
 
............................................................................................................................................... 
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APPENDICES 
10.1 Appendix 1 
Sample question and response 
What do you like most about being a scientist? Everyday is different –***** –enjoy being 
able to take initiative on tests and ***** –enjoy the work and people  
 
What are you good at? Give me some examples –good multitasker –good planner –don’t like 
**** –good at work practice 
 
When you think about bureaucracy what thoughts or feelings do you get? By bureaucracy I 
mean: Official procedure, Red tape, Rules and regulations, Formalities, Paperwork. There is 
no right or wrong answer here. I only want your opinion as related to your job as a scientist. 
Are there any issues here? 
We don’t always get credit for the work done. –those at coal face don’t always get 
recognition and this applies across whole organisation from what we hear gets talked about-
certain favorites get funds for conferences and merit pay and projects and the sexy stuff.-
possibly a combination of personality and ability but some quietly proceed with work but 
don’t get feedback and recognition. E.g. (so and so) developed a **** in their own time 
which the health laboratory claimed the IP for  and made lots of money but the individual 
scientist got no royalties –there is no difference made to those who work and those who don’t 
-there needs to be something in it for me to encourage scientists. 
 
Would others feel the same way? Yes –in ** years working I’ve noticed in the last **years 
there are more middle managers creating more memos and manager ‘speak’ to  
Justify their positions –this is the organisation culture now. 
 
What about management: It seems there is a lack of ability of bosses to give good feedback – 
with more managers I fail to see what they do –how many managers do we need?  
 
What about the Government -is there anything they can do to help: Long term development 
comes from scientists so if cut backs are caused by lack of finance or short term gain in 
employing fewer of us ultimately future progress will suffer 
What about the registration board and ****? –not asked 
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One manager said to me that the scientists are not publishing enough –some haven’t published 
for years –true some haven’t and this is the role of the scientific officer if they are into method 
development and if they want to maintain that role they need to publish more. –however, over 
the years they have been told to do more diagnostics work so they are doing more MLS work 
 
Do others at different levels feel this way? - Not asked for this participant  
 
Do other scientists in say, private labs feel this way?-not asked  
 
Human Recourses department people –can they do anything –they only do what they are told. 
 
Getting back to the earlier question of could you be any better- what would you or 
management need to change in order to do better? The management thinks we are top heavy 
with scientists (masters and PhD types) and if we went on strike it would take 3 weeks before 
anyone felt the effect. If MLSs strike it is felt straight away. However, what management 
doesn’t appreciate is that the scientific officers develop new methods and tests and for the 
MLS.-there is a role change as MLS have moved up and closed the gap and expectations 
between MLS and scientific officers so the management have tried to bring us down to the 
same level and pay less.-however, as an example one scientific officer set up a new assay 
which now do 100 samples a week and make $5000 a week- when there is a problem and the 
system falls over they call the scientific officer to fix it as the MLS have no time or ability to 
fix it. 
The organisation wants to reduce the number of scientific officers but in 10 years most of the 
senior ones will have retired anyway. –who will do the development that is expected of the 
PhD and masters type scientists –the MLS’s won’t have time and will they have the rigorous 
training and ability that comes with the extra study years? MSOs do more method 
development and pass it down.  
Scientists doing research need opportunity to a make the demarcation between MLS and 
scientific officers but because some do diagnostics they don’t get the time or opportunities as 
much to do research and publish –because some do all research and no diagnostics they get 
all research and have more opportunity to publish. –medics get increase to attend 
conferences e.g. $16000 –scientists don’t. 
  
76 
 
 
 
There is no short term or medium term or long term development –development is ad hoc – 
projects such as assays get developed then die –we need to identify the projects that will be 
useful for us to further develop and not waste time on developing things that can already be 
done quickly and efficiently already in England.-we need to improve and develop new tests 
and methodology and medics need to tell us what will have a future for us to develop. 
In the process of developing work others up the line can commit us and those further down 
the line to work without checking to see if the people are in a position to do the work. (Gave 
example here) 
When I write up my assignment the management might see the overall result –doesn’t worry 
me. 
 
 
 
 
10.2 Appendix 2. 
 
Sample responses from Medical laboratory scientists 
 
Medical Laboratory Scientists Group. –Government & Registration issues 
When you think of bureaucracy what thoughts and feelings do you get? By bureaucracy I 
mean: Official procedures, Red tape, rules and regulations, Formalities, Paperwork. There is 
no right or wrong answer here. I only want your opinion as related to your job. Are there any 
issues here? Responses here relate to Government and Registration body rather than 
management. 
1. The government made bureaucrats but they don’t have to accept the responsibility. E.g. 
CEO has high salary but they don’t have to justify it. Compliance regulations have us 
caught and trapped tying us in knots.-Q.A. is good but compliance is costing too much 
and they keep moving the goal posts to justify what they do and this costs us a bomb. 
Our union rep boosts moral and has done a great job for us but the management see 
him as a nuisance –he is severely curtailed but he does the job because he has a 
passion for staff – he is a great resource. 
2. There is lots of paper work –sometimes too much but it is necessary for records, 
fairness and day to day running –I can delegate because it’s a big section delegating 
helps give delegees a sense of ownership. We could visit other labs as there is open 
communication and we can work together. NZMLS Registration board is aware 
scientists are not recognized for what they do. For research and diagnostics we need 
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more funding –more staffing as staff feel the pressure. 
3. Has to be done –but appears to be too much bureaucracy. What about the registration 
board and NZIMLS? We need to be registered for clinical work –at first I thought it 
was silly but now see it as ok –possibly puts our esteem up –possible helps on safety 
issues –doesn’t do any harm –although we advertise in Australia and UK we can’t get 
enough staff –the ones who come are not just for money but for lifestyle. 
4. As part of NZ Blood service our section is based in hospital whereas other sections are 
outside. We are more involved with patients. –We should be part of hospital –while 
NZBS is excellently run, they don’t really know what we do in our section. We can’t 
just go home at 5:00pm we stay and tests are needed outside of normal hours-however 
we have to say we can’t do the tests because NZBS doesn’t offer this service now. The 
test then will take a lot longer to get done as it goes through a private lab. At least we 
are part of a national body –NZBS which is a good thing –we are now half way back to 
how things were. 
5. Nil 
6. Its not good having to strike –wages too low (gave examples).Not happy with 
Registration Board –doesn’t give feedback-one person had pharmacy degree but was 
initially declined registration –a Philippines scientist came here but was put as 
technician-a south African came and was accepted –a French scientist came and one 
was accepted but other not –same qualifications –seems to depend on who the 
examiner is –techs actually do same work but can be abused. 
7.  I’m not a member of NZIMS and I don’t check their website –unions are good at 
sorting problems- our registration board requires we do Prof Development and what 
they do is enough as I don’t want them being nosey and creating more work-their site 
is user friendly. Need more funding for Health –I think Government is culling 
Management 
8.  IANZ stuff is s**t and pedantic –but certain aspects necessary – some aspects are too 
nitpicky- they have run out of ideas but think they need to come up with stuff but this 
doesn’t improve things as some don’t get to the real issues but pick on extremes –
creates more paperwork. Not enough money forces management to buy cheaper 
equipment rather than listen to clinicians preference 
9.  I think of legislation as to protect –one need to understand the system which takes a 
long time to do –difficult to change things and bureaucracy is a barrier to change –
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bureaucracy is improving for some –but some have lack of autonomy in their jobs. We 
need more money– Govt should realize value of MLS and we weren’t mentioned in a 
report but we contribute to the DHB budget –Labs are too unrecognized –I would like 
to see more young people into science. Government could help set up research labs as 
separate with half pure science and half applied –hospital labs should primarily be in 
patient care. –About funding, soft money goes to hematology but no one gives to 
microbiology –scientists should make more noise to channel public perception. –We 
need good PhD’s and scientists but career structure is poor –career in science is good 
for women but not for men. - we are constrained by working for DHB as the structure 
doesn’t allow us to develope our own ideas –we are primarily here to serve the patient 
which constricts some personal science ideas we may wish to develop as the ideas must 
translate into patient care.–About funding, soft money goes to hematology but no one 
gives to microbiology –scientists should make more noise to channel public perception.  
 
10. They can stop or make it illegal for DHB’s to pay bonuses to managers –this is the 
problem and the management are ‘threatened’ not rewarded. They are threatened to 
have bonus’s cut –the bonus is actually a threat not a bonus. We are heading into 
‘creating a Revolution –we are not creating evolution –we are creating “revolution” 
The conditions are heading this way –this is what we are in now- we are heading for 
revolution. Look at the pay –scientists earn a lot less than others over there (hospital) 
who are doing less. 
11.  Doesn’t affect me –no issues. We need more money for research –we can’t comment as 
to where the money is to go as they decide. About Registration board and NZIMLS or 
MLSB? These are good as they help keep technologist and techs in touch –attending 
conferences contributes to CPD points. Science in NZ is underpaid but I do job 
because I love it –they need to pay more to keep people in it –prestige is ok –public 
awareness does make a difference by helping with private fund donations 
12.  Reliance on overseas such as suggested by Jenny Shipley and others is naive –we 
can’t import everything and if we do people who are the top drivers and world 
renowned like Dr *** would leave. 
13.  What about the registration board and NZIMLS? No can’t do anything –their 
bureaucracy is not required although conferences are well run by the institute –the 
board is not needed as much as they think they are.  The government problem is 
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allocating money in the wrong places –more input at the coal face is required 
14. Government has helped with pure science (Marsden?) PSA has helped us with pay –
NZIMLS helped with Prof Development but IMLTB is a pain in the neck 
15.  We try not to let it affect us but with IANZ accreditation some aspects of bureaucracy 
make it better but some aren’t – takes too much time writing up stuff for our CPD proff 
development - What about the registration board and NZIMLS? –We need this for our 
protection –but no point for those who don’t have to take responsibility for decisions - 
technicians also now have to have registration if they do clinical work. –but its not 
particularly helpful –does it really matter or make us better –for CPD if we do 
60points or 80 what real difference does it make to our performance? 
16.  We are always under funded- What help is NZIMLS? It is proactive- support special 
interests groups –have big scientific meetings –good notification 
17.  Government have been very helpful in our area of cervical screening by consolidating 
and streamlining labs –this is good for country and accepted by staff as a good thing 
but the unknown aspect of how the changes affect our jobs is stressful –massive 
increase in workload which is stressful. What about the registration board and 
NZIMLS? -Good thing as it gives more faith in co workers and me. Initiated CPD 
which is good but cumbersome and a lot of paperwork –have to do CPD in lunchtime 
meetings or own time.  
18. Don’t know –we are now in more automated equipment –so long as Government don’t 
obstruct. What about the registration board and NZIMLS? –Not really good as it makes 
people go to irrelevant stuff –not necessarily the best way –we should have continuing 
exams as refreshers 
 
 
10.3 Appendix 3 
Medical Laboratory Scientist Group.  
What do you like most about being a scientist? 
1. Love job –feel it makes a difference to patient –enjoy people –challenge –collegiality 
among scientists and techs - gets me out of home 
2. Patient contact first –helping patients- most others would possibly say the same, of 
course there are other reasons like staff contact, the job work, science etc. Money is 
not main reason-hardly anyone would say that. 
3. Variety –interesting cases and aspects and can follow these through – we see patient 
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4. Job security-but I like challenge-lifestyle better than teaching –routine could be boring 
but we can make decisions which are meaningful-the reference lab is well organized –
helping patients ––like being responsible although work is often routine.-like 
opportunity to be on call and making decisions after hours which help. I like being able 
to work part time. Money pathetic. 
5. Challenge of the hunt –we are looking for abnormalities and searching for an answer –
like working with people but I spend a lot of time alone looking down a microscope 
which is a slight downside to job. 
6. Close contact with staff –being part of a team –doing something –helping people-
dealing with mothers and babies and patients –patients and family and friends come to 
visit and our location of lab makes that possible as its off main thoroughfare in 
hospital. What about money –is that important to you? Well that’s why we don’t have 
enough scientists- we get below nurses –we are also dealing with life and death –our 
training is longer but nurses start at a much higher salary. 
7. The job is worthwhile 
8.  Diagnostic work, finding & providing a service –making people get better –every day 
is different –enjoy the people aspect –seeing staff grow –helping them- as section head, 
trying to make it a better place to work. 
9.  Enjoy mental stimulation –hands on work –hate having to do Management –like new 
challenges –don’t like routine – could do job with eyes closed but this is not what we 
do as we add value which differentiates us from private labs –like arriving at the 
correct method. I looked at a job their but withdrew my application because it did not 
add the value that the hospital scientist could achieve and it would be too routine.-here 
we have an opportunity to do research which they may not have in the private lab –they 
have pressure to do the numbers but the quality may be questionable and they don’t 
spend the extra money to do extra’s on certain patients. 
10. I like working with technology and up to date equipment –like the satisfaction of 
providing good results to clinicians – like making changes to procedure and processes- 
Like the clinical contact by phone regarding patient tests. 
11.  I do more good than harm –make a difference- preventive medicine 
12.  Being able to produce results for clinicians –our area is  now more automated or 
mechanical but 60% is still manual 
13. Job is unique –variety –I have 2 main areas and in charge of one –very interesting –we 
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are close to patients here and this makes it interesting 
14. Work is easy and I enjoy work and getting it right and on time- enjoy technical hands 
on and also theory –enjoy the routine and happy to do spadework 
15. When I started it was all hands on doing chemistry or hematology and I enjoyed that –
enjoy the feeling that maybe I’m helping someone –feels like I’m doing good. 
16. I like to think we improve the quality of health care which is my reason for being here –
surrounded by people more skilled than me – being part of a team that drives changes 
17.  Enjoy coming to work each day –variety in research –I’m a manager dealing with 
people 
18. Love job –feel it makes a difference to patient –enjoy people –challenge –collegiality 
among scientists and techs - gets me out of home 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
